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The thesis is focused on the molecular genetics of gynecologic cancers, 
specifically uterine serous carcinoma (USC) and ovarian clear cell carcinoma (OCCC), 
two relatively uncommon cancer types with aggressive clinical behavior. In the first 
project, we sequenced 10 exomes of USCs and validated the most frequent somatic 
mutations in 66 additional USCs. In addition, gene copy number was characterized by 
single-nucleotide polymorphism (SNP) arrays in 23 USCs. Frequent somatic mutations 
were identified in TP53 (81.6%), PIK3CA (23.7%), FBXW7 (19.7%), and PPP2R1A 
(18.4%) in USCs. Concordant PIK3CA, PPP2R1A, and TP53 mutation status between 
USC and the its precursor lesion, serous endometrial intraepithelial carcinoma (SEIC), 
were recognized in all SEICs examined. DNA copy number analysis revealed frequent 
genomic amplification of the CCNE1 locus and deletion of the FBXW7 locus. Among 23 
uterine serous carcinomas that were subjected to SNP array analysis, seven tumors with 
FBXW7 mutations did not have CCNE1 amplification, and 13 (57%) tumors had either a 
molecular genetic alteration in FBXW7 or CCNE1 amplification. Nearly half of these 
uterine serous carcinomas harbored PIK3CA mutation and/or PIK3CA amplification. This 
study implicated genetic aberrations of the p53, cyclin E–FBXW7, and PI3K pathways as 
major mechanisms in the development of USC. In the second project, I evaluated in 525 
gynecologic cancers the prevalence of gain-of-function TERT promoter mutations, which 
have been shown to promote transcriptional activation of TERT and likely play a key role 




carcinomas (OCCC), of which 15.9% harbored the mutations, the majority of 
gynecological malignancies were wild-type. TERT promoter mutation does not appear to 
be an early event during oncogenesis, as it was not detected in the contiguous 
endometriosis associated with OCCC. OCCC cell lines with TERT promoter mutations 
exhibited higher TERT mRNA expression than those with wild-type sequences. TERT 
promoter mutation tended to be mutually exclusive with loss of ARID1A protein 
expression and PIK3CA mutation in ovarian clear cell carcinomas. These results suggest 
that aberrations in telomere biology may play an important role in the pathogenesis of 
OCCC. 
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Gynecologic cancer is complex and heterogeneous, encompassing a huge family 
of neoplasms with different histopathologic and molecular genetic features. On the one 
hand, a myriad of cancer subtypes can arise in each of the organs in the female 
reproductive system (1). For example, the epithelial cancer affecting the ovary comprises 
of at least four major carcinoma subtypes defined by their histopathologic attributes, 
including serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous 
carcinoma (1,2). At times, it can be a challenging task to classify ovarian carcinomas by 
histopathology alone, as they occasionally develop with mixed or borderline histologic 
features. On the other hand, cancers of similar histopathology can affect different parts of 
female reproductive system. For instance, clear cell carcinoma, high grade serous 
carcinoma, and endometrioid carcinoma can develop in either uterine endometrium or 
ovary (1,2). Though showing similar histomorphology, these cancers arising in different 
parts of female genital organs likely feature distinct molecular genetic aberrations. 
Hence, careful study of molecular genetics of cancer subtypes will help fine tune the 
classification of cancers and provide a guidance for risk prognostication and personalized 
treatment. In this thesis research, we set out to study the genetic alterations of 
gynecologic cancers, focusing on serous carcinoma arising from the uterine endometrium 
and ovarian clear cell carcinoma.  




and the fourth most common malignant neoplasm among women in the United States (3). 
The incidence rate of endometrial cancer has been steadily increasing after the 
precipitous decline in menopausal hormone replacement therapy since 2002 (4). It is 
estimated that in 2014, about 52,630 new cancers in the uterine corpus, most of them 
endometrial cancers, will be diagnosed in the United States, and 8,590 will die from 
cancers in the uterine corpus (5). Endometrial carcinoma is traditionally classified as type 
I and type II, based on the epidemiological and clinical findings (6). Type I endometrial 
carcinomas are estrogen dependent and develop from endometrial hyperplasia, whereas 
type II carcinomas are estrogen independent and arise in atrophic endometrium or 
endometrial polyps. Histologically, type I carcinomas are generally of endometrioid 
subtype, and type II are composed mainly of serous carcinoma, which resembles ovarian 
high grade serous carcinoma histologically and clinically. Uterine serous carcinoma tends 
to occur in older women and often presents at an advanced stage. Although uterine serous 
carcinomas constitute only 10% of all endometrial cancers, they account for a 
disproportionately high number of deaths (7). This highly aggressive behavior can be 
attributable to the unique tendency of uterine serous carcinomas to disseminate to 
peritoneal cavity even when the primary tumor is small; in addition, uterine serous 
carcinoma is highly resistant to conventional chemotherapy, and recurrence is inevitable 
in most patients with advanced-stage disease.  
 The first half of the thesis is focused on delineating the genetic landscapes of 
uterine serous carcinoma. In this project, we performed whole exome sequencing on pairs 
of uterine serous carcinoma and non-tumor tissue and validated the most frequent somatic 




uterine serous carcinoma with single-nucleotide polymorphism (SNP) arrays. Moreover, 
we interrogated which gene mutations were early events during the oncogenesis of serous 
carcinoma by sequencing serous endometrial intraepithelial carcinoma, the pre-invasive 
lesions of uterine serous carcinoma. This study identified genetic aberrations of the p53, 
cyclin E–FBXW7, and PI3K pathways as major mechanisms in the development of 
uterine serous carcinoma. The details and implications of this study will be elaborated in 
Chapter 2.  
The second half of the thesis is devoted to a study on the genetic alteration of 
telomerase reverse transcriptase (TERT) in gynecologic malignancies. Telomeres protect 
the ends of eukaryotic chromosomes from inappropriate triggering of DNA repair 
machinery that may cause chromosome end to end fusion (8). Telomere dysfunction, 
either through shortening of telomeric DNA or loss of function of telomere-capping 
proteins, results in a DNA damage response that activates p53 tumor suppressor gene, 
which induces replicative senescence or apoptosis. If p53 function is lost, these responses 
to telomere dysfunction are mitigated and chromosomal fusion ensues (9). The fused 
chromosomes are di-centric and may be broken during mitosis (10). These broken ends 
serve as catalysts for further chromosome structural aberrations if telomere function is 
not restored (11). To maintain unlimited replication potential, cancer cells evolve 
mechanisms to maintain telomere length (11). Most cancers, especially carcinomas, 
maintain their telomere length by increasing the activity of telomerase reverse 
transcriptase, the catalytic unit of the telomerase that extend the telomeric nucleotide 
repeats to the end of chromosomes (12). This is achieved through a variety of 




activators of TERT (14) and CpG methylation at the TERT promoter (15).  
Recently, somatic mutations at the TERT promoter in human cancer have been 
reported in several cancer subtypes , including malignant melanoma, glioma, urinary 
bladder carcinoma, tongue squamous cell carcinoma and hepatocellular carcinoma (16-
20). Such mutations were thought to promote the transcription of TERT (16,17). The 
prevalence and clinical significance of TERT promoter mutations in gynecological 
malignancies remains largely unclear because noncoding regions, including promoter 
sequences, were not routinely included in large-scale genomic analyses. In this study, we 
performed mutational analysis in a total of 525 gynecological malignancies, and 
correlated TERT promoter mutations with clinicopathological features. We found that 
TERT promoter mutation is most prevalent in ovarian clear cell carcinoma. TERT 
promoter mutation is associated with higher TERT mRNA expression in cell lines 
derived from ovarian clear cell carcinomas. Furthermore, TERT promoter mutation is 
mutually exclusive with ARID1A loss and PIK3CA mutation, the most common genetic 
aberrations in ovarian clear cell carcinoma. The results of this study will be detailed in 




2	  Integrative	  Genomic	  Analysis	  of	  
Uterine	  Serous	  Carcinoma	  	  
	  
Endometrial carcinoma is the most frequently diagnosed gynecological cancer 
and the fourth most common malignant neoplasm among women in the United States (3). 
Traditionally, endometrial carcinoma is classified into two main groups: type I and type 
II (6). Type I endometrial carcinoma is composed of low-grade endometrioid carcinoma, 
and type II is composed mainly of uterine serous carcinoma. Uterine serous carcinoma 
occurs in older women and often presents at an advanced stage. Low-grade endometrioid 
carcinomas are estrogen dependent and develop from endometrial hyperplasia, whereas 
uterine serous carcinomas are estrogen independent and arise in atrophic endometrium 
and endometrial polyps from pre-invasive lesions known as serous endometrial 
intraepithelial carcinoma. Although uterine serous carcinomas constitute only 10% of all 
endometrial cancers, they account for a disproportionately high number of deaths (7). 
This highly aggressive behavior is related mainly to the unique tendency of uterine serous 
carcinomas to metastasize even when the primary tumor is small; as a result, most 
patients with uterine serous carcinoma have metastatic disease, which is not curable, at 
the time of diagnosis. Moreover, uterine serous carcinoma is highly resistant to 
conventional chemotherapy, and recurrence is inevitable in most patients with advanced-




understood, therapeutic interventions to improve the clinical outcomes of these patients 
remain empirical. 
Previous molecular genetic studies of endometrial carcinoma have focused on 
low-grade endometrioid carcinoma (21,22). More recently, the genome-wide molecular 
changes in endometrioid carcinomas, especially those of low grade, have been revealed 
through the efforts of The Cancer Genome Atlas. By contrast, the molecular genetic 
changes that account for the malignant behavior of uterine serous carcinoma are largely 
unknown. Thus, the purpose of this study is to elucidate the molecular genetic 
characteristics of uterine serous carcinoma by cataloguing the genetic alterations detected 
by whole-exome sequencing and gene copy number analysis, with emphasis on 







2.1.1	  Tissue	  Specimens	  and	  Genomic	  DNA	  Preparation	  
A total of 76 uterine serous carcinomas were studied in this report: six fresh 
tumors from which we affinity purified tumor cells (designated by the suffix "TS" or "S") 
and four frozen tumors (designated by the suffix "T") were used for discovery, and 66 
tumors including 34 frozen tumors and 32 paraffin-embedded tumors were used for 
validation. Normal tissues were designated with the suffix "N." The diagnosis of uterine 
serous carcinoma was confirmed in all tumors according to previously described 
diagnostic criteria (1,2) by three gynecological pathologists based on review of the 
hematoxylin and eosin–stained slides. The tumor cells from the six of the 10 specimens 
in the discovery set were isolated by digestion with collagenase I (Roche, Indianapolis, 
IN), followed by epithelial cell enrichment using Dynabeads coated with EPCAM 
antibodies (Invitrogen Inc., Carlsbad, CA). We performed immunocytochemistry using 
an anti-cytokeratin antibody (prediluted, CAM5.2; Becton Dickinson, Franklin Lakes, 
NJ) to ensure that more than 90% of cells in the purified samples were epithelial cells. 
Affinity purification of tumor cells and immunocytochemistry were performed as 
previously described (23,24). Genomic DNA was extracted from both tumor and normal 
cells with the use of a DNeasy Blood and tissue kit (Qiagen, Inc., Valencia, CA) 
according to the manufacturer's protocol. 
The validation set comprising 66 uterine serous carcinomas was obtained from the 




(New york, NY), and University of Toronto Health System (Toronto, NN, Canada). 
Among tumors from discovery and validation sets, nine contained serous intraepithelial 
carcinoma, a preinvasive (in situ) uterine serous carcinoma component, which was 
isolated by laser-capture microdissection. Genomic DNA was isolated from all validation 
set samples as described above and was subjected to Sanger sequencing analysis. Patient 
consent information was not available because we used anonymous tissue materials that 
lacked patient's identification. The use of de-identified tissue material was approved by 
the Institutional Review Boards of Johns Hopkins Hospital, Memorial Sloan-Kettering 
Cancer Center, University of Toronto Health System, and the National Taiwan University 
Hospital. 
 
2.1.2	  Whole-­‐Exome	  Sequencing	  of	  the	  Discovery	  Set	  
Exome DNA capture was performed with the use of a TruSeq exome enrichment 
Kit (Illumina, San Diego, CA), and paired-end libraries were constructed with the use of 
a TrueSeq DNA Sample Prep Kit (Illumina) as previously described (23). Paired-end 
sequencing (100-bp reads × 2) was performed with the use of a HiSeq Analyzer 
(Illumina) provided by Illumina's fast track genetic analysis service. Whole-exome 
sequencing was also performed on DNA isolated from the matched normal tissues 
(peripheral mononucleated blood cells or myometrium) from each of the 10 patients who 
had tumor tissue in the discovery set. 




aligned to the human reference sequence known as the National Center for Biotechnology 
Information (NCBI) Build 36 (ftp://ftp.ncbi.nih.gov/genomes/h_sapiens/ArChIVe/ 
BuILD.36.3/) using the Burrows–Wheeler Aligner (version 0.5.5) (25), and reads were 
removed using the Picard package 1.29 (http:// picard.sourceforge.net). The total number 
of sequencing reads and mapping statistics were assessed by using the flagstat function of 
Samtools (version 0.1.7) (25). 
The effective coverage of the whole exome was obtained by summarizing the 
coverage of aligned bases using the Coverage module of Bambino. We only included 
sequencing reads with a quality score of 15 or higher so that the expected error rate was 
less than 5% at each position of the reference human exome (26). We considered a base 
as covered if the effective coverage was at least 10-fold. We also excluded all ambiguous 
bases and sequencing gaps in the human reference sequence from our coverage analysis. 
The exome annotation was based on NCBI RefSeq (27). 
 
2.1.3	  Detection	  of	  Somatic	  Sequence	  Mutations	  
Putative sequence mutations, including single-nucleotide variations, insertions, or 
deletions, were initially detected by using the variation detection module of Bambino 
(26). Specifically, the analysis was run using three different parameters as previously 
described (28,29): a) a high-quality threshold (minimum quality score set to 20) for 
pooled tumor and matching normal tissue BAM files; b) a low-quality threshold 




files; and c) a high-quality threshold (minimum quality score set to 20) for normal tissue–
only analysis (see definition of minimum quality score at 
https://cgwb.nci.nih.gov/goldenPath/bamview/ documentation/index.html). The pooled 
tumor–normal tissue analysis reduces the possibility of misclassifying germline 
variations with poor coverage in matching normal tissue samples as somatic mutations. 
Variants identified by normal tissue–only analysis were removed for further 
consideration, whereas those only identified by paired tumor and normal tissue analysis 
were subjected to an automated review process to remove additional false-positive calls 
caused by misalignment or mismapping of whole-exome sequencing reads. Specifically, 
the automated review process firstly used the Smith–Waterman algorithm to realign all 
reads that harbored the mutant allele, followed by quality and alignment trimming, then a 
double-strand coverage check for the variant allele, and a final remapping of reads that 
harbored the minor allele to the reference genome to ensure uniqueness. 
 Transcripts from NCBI RefSeq (build download may 21, 2009) (27) were 
used for annotation. Variants were classified as coding synonymous ("silent"), missense, 
nonsense, intronic, regions within 10bp of a canonical splice site, splice site, or 
noncoding RNA variants, as well as those that occurred in 3′ and 5′ untranslated regions. 
The insertions and deletions were further classified as frameshifts or in-frame insertions 
or deletions. 
2.1.4	  Analysis	  of	  Background	  Mutation	  Frequency	  
Assuming that the silent codon position is selectively neutral, we used the 
11 
mutation rate at this position to approximate the background mutation frequency. 
Specifically, the background mutation frequency (µ) can be calculated by the following 
equation: 
 
where M is the total number of validated silent somatic mutations in each tumor 
sample (ie, the nonfunctional background mutations), Ne is the total number of 
effectively covered coding bases (ie, simultaneously covered by ≥10-fold in both tumor 
and matching normal tissue) in all RefSeq protein coding genes, and β is the silent-to-
nonsilent ratio [estimated to be 0.350 by the TCGA Consortium (30) across the coding 
regions. 
2.1.5	  Sanger	  Sequencing	  for	  Validation	  of	  Putative	  Mutations	  
Putative mutations identified by whole-exome sequencing were validated by 
conventional Sanger sequencing of both tumor and normal DNA (from peripheral blood 
mononucleated cells or myometrium) samples in the discovery set. Before Sanger 
sequencing, genomic DNA containing the putative mutations was amplified by 
polymerase chain reaction (PCR) with the use of primers that flanked the putative 
mutations. We also used the Sanger method to sequence DNA isolated from the 66 
uterine serous carcinomas and matched normal tissue in the validation set to identify the 




analyzed using Mutation Surveyor software (version 4.0; SoftGenetics, State College, 
PA). 
 
2.1.6	  Single-­‐Nucleotide	  Polymorphism	  Array	  and	  DNA	  Copy	  
Number	  Analysis	  
We analyzed 23 uterine serous carcinomas for which there was sufficient material 
to examine DNA copy number changes by single-nucleotide polymorphism (SNP) arrays. 
These included 10 samples from the discovery set and 13 frozen tumors from the 
validation set. SNPs were genotyped using 250K StyI arrays (seven tumors) or SNP 
Array 6.0 (16 tumors; both arrays from Affymetrix, Santa Clara, CA) at the microarray 
core facility at the Johns Hopkins University according to manufacturer's instructions. In 
addition, 13 uterine endometrioid carcinomas from the National Taiwan University 
Hospital were analyzed for copy number alterations using the 250K StyI arrays. The SNP 
array data for 25 normal tissues, 12 ovarian serous borderline tumors, 12 ovarian low-
grade serous carcinomas, seven ovarian endometrioid carcinomas, 12 ovarian clear cell 
carcinomas, and 33 ovarian high-grade serous carcinomas were previously reported 
(31,32). 
The analysis of SNP array data was performed using the dChip software (2006 
version) as previously described (31,32). Only data corresponding to probes present in 
both SNP Array 6.0 and 250K StyI array were analyzed. To quantify the relative levels of 




calculate the genome-wide chromosomal instability index based on dChip analysis to 
infer the copy number. To identify the genes and regions with somatic copy number 
alterations (DNA copy number gain or loss as compared with matched normal tissue 
samples), the intensity of each probe was inferred with the use of Genotyping Console 
software (version 4.1.3; Affymetrix). To detect somatically altered chromosomal regions 
in the 23 uterine serous carcinomas, we used R package DNAcopy 
(http://www.bioconductor.org/packages/2.3/bioc/html/ DNAcopy.html) to perform 
circular binary segmentation analysis (33,34) and combined the segmentation results for 
all 23 uterine serous carcinomas. To identify the genes with statistically significant DNA 
copy number alterations, we used cghMCR 
(http://www.bioconductor.org/packages/release/bioc/html/cghMCR.html), an R 
implementation of a modified version of GISTIC analysis (35), because the original 
GISTIC algorithm only works for segmentation results from the same platform. Instead 
of the G score, which is reported by GISTIC algorithm, the cghMCR package uses a 
Segments-of-Gain-or-Loss (SGOL) score to indicate the frequency and degree of copy 
number changes in each gene or segment. Here, we selected three standard deviations 
(SDs) from the mean SGOL score as the cutoff because 99.7% of genes had SGOL scores 
within this range. In particular, we defined amplified genes as the genes with SGOL 
scores greater than 3 SDs of the mean SGOL scores and deleted genes as those with 






Immunohistochemistry for p53 and cyclin E1 expression was performed on 
paraffin-embedded sections of 41 and 37 uterine serous carcinomas, respectively, from 
both the validation and discovery sets. The detailed protocol for p53 
immunohistochemistry has been reported previously (36). Briefly, after antigen retrieval 
was carried out with Cell Conditioning 1 solution (Ventana Medical Systems, Tucson, 
AZ), the sections were incubated with a mouse monoclonal p53 antibody (clone Bp53-11, 
prediluted; Ventana Medical Systems) for 16 minutes at 37°C. Staining was detected with 
the use of an iView DAB detection system (Ventana Medical Systems). For cyclin E1 
staining, heat-induced epitope retrieval was performed with the use of Target Retrieval 
Solution (Dako, Carpinteria, CA), and nonspecific endogenous peroxidase activity was 
blocked by treatment with 3% hydrogen peroxide. The sections were then incubated with 
a polyclonal rabbit cyclin E antibody (1:250 dilution; Sigma-Aldrich, St Louis, MO) at 
room temperature for 65 minutes, followed by antibody detection with the use of an 
LSAB kit (catalog # K0690; Dako). Cyclin E1 immunoreactivity was visualized by a 
peroxidase reaction (Dako), and the sections were counterstained with hematoxylin 
(Dako). 
 
2.1.8	  Chromosomal	  Instability	  Index	  Analysis	  
We used the genome-wide chromosomal instability index to quantify the degree 




(32). the genome-wide chromosomal instability index was defined as log(C1 + 1) + ... + 
log(Ci + 1) + ... + log(C23 + 1), where C1, Ci, and C23 are the chromosomal instability 
indices for chromosomes 1, i, and 23 (X chromosome), respectively. the chromosomal 
instability index for each chromosome was calculated as the sum of magnitudes of all 
subchromosomal segments whose copy numbers were amplified or deleted. The 
magnitude of an amplified copy number segment was the average intensity of SNP 
signals within the segment. The magnitude of a deleted copy number segment was 
normalized by the transformation 2.5 + (R − 2.5)(1.5 − x)/1.5, where x was the average 
intensity of SNP signals within the segment and R was the maximum magnitude of 
amplified copy number segments across all samples. 
 
2.1.9	  Statistical	  Analysis	  
We used one-way analysis of variance (ANOVA) followed by the Tukey–Kramer 
test for multiple comparisons to examine whether the chromosomal instability index for 
uterine serous carcinoma was statistically significantly higher than that for other types of 
gynecological neoplastic diseases based on our previous report (32). The Fisher exact test 
was used to compare the frequency of somatic mutations of several candidate genes in 
uterine serous carcinoma with the previously reported frequency in high-grade serous 
carcinoma of the ovary (37); P values were adjusted using the Bonferroni method. The 
association between p53 immunopositivity and TP53 mutation status was evaluated by a 










2.2.1	  Paired-­‐End	  Whole-­‐Exome	  Sequencing	  of	  Uterine	  Serous	  
Carcinoma	  
To gain new insight into the genetic basis of uterine serous carcinoma, we 
determined the sequences of approximately 18,000 protein encoding genes in tumor and 
normal tissue samples from 10 uterine serous carcinomas by paired-end sequencing. To 
increase the sensitivity of somatic mutation detection, we used DNA extracted from 
epithelial tumor cells that were affinity-purified from six fresh tumor specimens with the 
use of EpCAM antibody–conjugated beads. Immunohistochemical staining of the 
purified cells with a cytokeratin antibody verified that more than 90% of each tumor was 
of epithelial origin. Our use of a high-throughput, paired-end sequencing system resulted 
in more than 75 million reads per DNA sample. The mean mapping rate for total reads 
was 98.4% (SD = 0.4%), and the mean percentage of targeted bases that were covered by 




Table 2-1. Mapping statistics and the coverage of whole-exome sequencing of 10 uterine serous carcinomas 
(discovery set) 








Mean no. of reads 
 







900T 115,779,238 98.53 61.9 52 89.8 80.2 69.9 
900N 111,798,422 98.27 60.2 56 90.8 82.4 73 
366TS 125,512,762 98.65 64.1 58 91 82.7 73.7 
366N 151,883,024 97.74 74.4 65 92.4 85.5 77.4 
702TS 199,251,410 97.86 99.4 85 94.1 89.6 84.2 
702N 76,933,210 98.02 35.9 33 85.2 69.6 52.8 
863TCS 108,667,726 98.27 54.6 50 90.3 80.9 70.1 
863N 113,439,292 98.03 61.5 58 91.8 84.5 75.7 
340TS 111,431,136 98.64 52.1 46 89.8 79.6 67.9 
340N 84,684,952 98.79 41.7 38 88.3 75.3 60.3 
993TCS 110,439,740 98.84 53.3 45 84.7 72.9 62 
993N 105,576,046 98.75 54.6 50 88.5 78.3 67.6 
FM403T 107,195,624 98.83 51.9 43 87.5 75.4 63 
FM403N 121,779,982 98.60 63.6 59 90.7 82.6 73.7 
DM851T 115,971,750 98.59 61.9 56 89.2 80.1 70.8 
DM851N 116,959,022 98.57 60.1 56 90 81.2 71.7 
FM474T 106,664,394 98.55 50.9 47 89 79.1 67.9 
FM474N 106,243,310 98.76 58.3 53 90.7 81.8 71.6 
555TS 212,645,988 97.91 101.9 92 94.9 91.4 87 
555N 106,972,698 98.06 44.3 43 89.8 79 65.9 





     We identified 946 somatic mutations in 874 genes among 10 uterine serous 
carcinomas using the method reported in the analysis of whole genome sequencing data 
of T-cell precursor acute lymphoblastic leukemia and retinoblastoma (28,29). To ensure 
that our method could reliably detect somatic mutations, we re-sequenced 331 randomly 
selected mutated regions (mainly those containing non-silent mutations) by Sanger 
sequencing and verified that 303 (91.5%) contained the originally identified mutation 
(Appendix 1). 
The median number of somatic sequence mutations for uterine serous carcinomas 
in the discovery set, including synonymous and nonsynonymous changes, alterations in 5′ 
and 3′ untranslated regions, and alterations in noncoding RNA, was 96 (range = 38–156) 
(Table 2-2). The median number of somatic nonsynonymous and splice site mutations for 
uterine serous carcinomas in the discovery set was 38 (range = 10–64). The most 
common sequence mutation in these 10 uterine serous carcinomas was a C to T or G to A 
transition (Figure 2-1). Specifically, there were 454 nonsynonymous and splice site 
mutations in 425 genes (Appendix 1), and the average nonsilent-to-silent mutation ratio 






Table 2-2. Detailed mutation profiles in the discovery set of uterine serous carcinomas* 
 





















CDS SNV           
Missense 35 17 58 42 6 23 56 32 57 18 
Nonsense 6 0 3 3 3 2 3 2 5 0 
Silent 17 5 14 16 5 9 30 12 17 9 
Splice site SNV 7 3 6 9 2 2 3 3 11 6 
Non-silent SNV 48 20 67 54 11 27 62 37 73 24 
Indels           
Frameshift 4 1 1 4 1 2 3 4 3 1 























5′ UTR 3 5 6 4 7 3 7 8 5 7 
Non-coding RNA 4 1 8 1 2 5 8 8 6 4 
Intron 2 0 0 0 0 1 1 1 1 1 
Total no. of somatic alterations 96 40 136 107 38 71 156 96 145 61 
 











































*CDS = coding sequence; SNV = single nucleotide variation; indels = insertions and deletions; UTR = untranslated region. 
†Background mutation rate = the total number of silent mutations normalized to the number of "covered" synonymous sites (approximately one-third of "covered" CDS bases).
21 
Figure 2-1. The mutation spectrum in 10 USC samples. The most common point 
mutation in those 10 USCs was from C(G) to T(A) transition. 
Among the 425 somatically mutated genes, 14 were mutated in two or more of the 
10 uterine serous carcinomas: TP53, PIK3CA, FBXW7, PPP2R1A, BSN, DNAH11, NEB, 
OBSCN, ORAI2, RNF19B, SLC28A1, SPTA1, UBA2, and UTRN (Table 2-3). To identify 
other cancer-related genes that are less commonly mutated in uterine serous carcinoma, 
we compared all genes harboring mutations from this study with the cancer-related 
mutations reported in the Cancer Gene Census database 
(http://www.sanger.ac.uk/genetics/CGP/Census/). This comparison yielded 16 genes: 
four genes (FBXW7, PIK3CA, PPP2R1A, and TP53) were mutated in more than one of 
the 10 uterine serous carcinomas, whereas 12 cancer-associated genes occurring in 




BCL9, BRCA2, ERCC5, KRAS, LHFP, MLL3, MYH11, NCOA2, NSD1, PDGFRA, and 
USP6). Of note, all three missense mutations detected in FBXW7 occurred at the Arg465 
hotspot (COSMIC database, http://www.sanger.ac.uk/ 
perl/genetics/CGP/cosmic?action=bygene&ln=FBXW7&start= 
1&end=708&coords=AA:AA), whereas none of the four PIK3CA mutations were located 
at previously reported exons containing hotspots. We found no mutations in mismatch 





Table 2-3.  Recurrently mutated genes in 10 uterine serous carcinomas of the discovery set* 
 
Gene Transcript         900T 366TS 702TS 863TCS      340TS      993TCS         FM403T      DM851T        FM474T      555TS Total 
TP53 NM_000546.4 c.677del  c.742C>T c.722C>T c.481G>A c.832C>A c.647_672+3del c.713G>A c.742C>T c.730G>C 9 
  p.G226Afs  p.R248W p.S241F p.A161T p.P278T p.V216Gfs p.C238Y p.R248W p.G244R  
PIK3CA NM_006218.2   c.1252G>A c.353G>A   c.1093G>A  c.1031T>G  4 
    p.E418K p.G118D   p.E365K  p.V344G   
FBXW7 NM_033632.2 c.1393C>T c.1394G>A      c.1394G>T   3 
  p.R465C p.R465H      p.R465L    
PPP2R1A NM_014225.3   c.767C>A       c.536C>G* 2 
    p.S256Y       p.P179R*  
BSN NM_003458.3  c.8374C>G  c.2687G>A       2 
   p.Q2792E  p.R896H        
DNAH11 NM_003777.3 c.3925G>A      c.6536T>C    2 
  p.A1309T      p.V2179A     
NEB NM_001164508.1    c.20330T>C   c.23491A>T    2 
     p.V6777A   p.I7831F     
OBSCN NM_001098623.1    c.11274_11275del      c.22967A>T 2 
     p.H3758Qfs      p.E7656V  
ORAI2 NM_001126340.1        c.214G>A c.397T>G  2 
         p.G72S p.S133A   
RNF19B NM_153341.2   c.842-5C>G    c.1264G>T    2 
    ex3_splice    p.G422C     
SLC28A1 NM_004213.3       c.1754G>A c.-16-1G>T   2 
        p.C585Y ex3_splice    
SPTA1 NM_003126.2 c.610del       c.3697G>A   2 
  p.Q204Kfs       p.V1233I    
UBA2 NM_005499.2   c.347T>C      c.223-2A>T  2 
    p.L116S      ex3_splice   
UTRN NM_007124.2    c.8782G>A     c.5074-1G>A  2 
     p.V2928I     ex36_splice   
 




2.2.2	  Prevalence	  Screening	  of	  Mutations	  in	  Selected	  Genes	  
We performed Sanger sequencing to determine prevalence of mutations in 
FBXW7, FBXW8, PIK3CA, PPP2R1A, PIK3C2B, PIK3R4, RNF19B, and TP53 in 34 
frozen tumors from the validation set with sufficient DNA. In addition, we sequenced 
known mutational hotspots in FBXW7 [coding exons 8 and 9; (38)], PIK3CA [coding 
exons 1, 9, and 20; (39)], PPP2R1A [coding exons 5 and 6; (23)], and TP53 (coding 
exons 4–9; COSMIC database, 
http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=byg 
ene&ln=tP53&start=1&end=394&coords=AA:AA) in an additional 32 paraffin-
embedded uterine serous carcinomas from the validation set. We also sequenced exon 9 
of FBXW8 in the 32 uterine serous carcinomas because a somatic mutation in this exon 
was identified in our discovery screen. RNF19B was selected for validation because it 
was somatically mutated in two of the 10 uterine serous carcinomas in the discovery set 
and it encodes an E3 ligase that ubiquitinates uridine-cytidine kinase-like 1 (UCKL1), a 
tumor survival factor (40-42). Although only one somatic mutation was found in the 
discovery set for FBXW8, PIK3C2B, and PIK3R4, these genes were chosen for validation 
because, similar to FBXW7, FBXW8 also contains F-box and WD-40 domains and 
functions as E3 ubiquitin ligase (43), and both PIK3C2B and PIK3R4 are involved in the 
phosphatidylinositol 3-kinase (PI3K) signaling pathway (44). The prevalence of somatic 
mutations in TP53, PIK3CA, FBXW7, and PPP2R1A in the validation set (n = 66) was 




carcinomas from the discovery and validation sets (n = 76), the prevalence of somatic 
mutations in TP53, PIK3CA, FBXW7, and PPP2R1A was 81.6%, 23.7%, 19.7%, and 
18.4%, respectively (Table 2-4); all mutations in these four genes in all 76 tumors are 
listed in Appendix 2. For FBXW7, there were 16 somatic mutations (15 mutations 
involved the coding region and one involved the noncoding region at the splice site) 
detected in 15 tumors among all 76 tested tumors; all FBXW7 somatic mutations 
involving the coding region occurred in the WD40 domain, whose function in E3 
ubiquitin ligases is to recognize phosphorylated ubiquitination signals (45). However, we 
did not detect any somatic mutations in FBXW8, PIK3C2B, PIK3R4, or RNF19B in the 
validation set. It should be noted that the higher mutation frequency of TP53 in the 
discovery set than in the validation set (90% vs 80%) may reflect the fact that we used 
affinity-purified tumor cells in some of the discovery samples. Accordingly, the actual 
prevalence of mutations in all the genes analyzed could be slightly higher than that 
reported in this study. 
 
 
Table 2-4. The prevalence of most common somatic mutations (frequency 














Discovery set 10 3 4 2 9 
Validation set (paraffin-embedded) 32 8 5 4 24 
Validation set (fresh frozen) 34 4 9 8 29 






To examine whether the TP53 mutation pattern was associated with p53 protein 
expression in carcinoma tissues, we performed p53 immunohistochemistry on 41 uterine 
serous carcinomas from both discovery and validation sets for which paraffin-embedded 
tissues were available. We found that 27 of 28 tumors bearing TP53 missense mutations 
or in-frame deletion had diffuse p53 staining. The frequency of diffuse staining in tumors 
with TP53 missense mutation or in-frame deletion was statistically significantly higher 
than in those with a null mutation or wildtype TP53 (96.4% vs 46.2%, P < .001, two-
tailed Fisher exact test). These findings are consistent with our previous report showing a 
similar association between p53 immunostaining pattern and TP53 mutation type in 
ovarian high-grade serous carcinomas and serous tubal intraepithelial carcinomas (36). 
In contrast, by analyzing 316 ovarian high-grade serous carcinomas from the 
ovarian cancer dataset of TCGA (37), we found somatic mutations of PIK3CA, FBXW7, 
and PPP2R1A in only 0.63%, 0.95%, and 1.27%, respectively (Table 2-4). The mutation 
frequencies of those genes were statistically significantly higher in uterine serous 
carcinoma than in ovarian high-grade serous carcinoma (P < .001, Fisher exact test; Table 
2-5). 
 
Table 2-5. Mutation rate comparison of PIK3CA, FBXW7, and PPP2R1A between 
uterine serous carcinoma and ovarian high-grade serous carcinoma 
 
Tumor type 
Somatic mutation rate 
PIK3CA FBXW7 PPP2R1A 
Uterine serous carcinoma 18/76 15/76 14/76 
Ovarian high-grade serous carcinoma 2/316 3/316 4/316 
Fisher exact test P value <.001 <.001 <.001 





2.2.3	  DNA	  Copy	  Number	  Alterations	  in	  Uterine	  Serous	  Carcinoma	  
and	  Other	  Gynecological	  Cancers	  
Because DNA copy number alterations are commonly associated with 
tumorigenesis (46), we also used the SNP arrays for copy number analysis of 23 uterine 
serous carcinomas (10 from discovery set and 13 from validation set) for which the 
genomic DNA was available for analysis. By using the chromosomal instability index, a 
quantitative measure of the genome-wide level of DNA copy number changes (32), we 
found that among a panel of gynecological tumors, uterine serous carcinoma displayed a 
mean chromosomal instability index comparable to that of ovarian high-grade serous 
carcinoma, a fatal subtype of ovarian cancer with known prominent genomic alterations 
(Table 2-6) (32,37). The mean chromosomal instability index for both uterine serous 
carcinoma (mean = 1.129) and ovarian high-grade serous carcinomas (mean = 1.475) was 
statistically significantly higher than that in other types of gynecological cancers, 
including uterine endometrioid carcinoma (mean = 0.298), ovarian serous borderline 
tumor (mean = 0.134), ovarian low-grade serous carcinoma (mean = 0.386), ovarian 
endometrioid carcinoma (mean = 0.228), and ovarian clear cell carcinoma (mean = 
0.302) (P < .001, one-way ANOVA followed by Tukey–Kramer test) (Figure 2-2 and 2-
3). The details of the chromosome instability index for each type of gynecological cancer 








Figure 2-2. Copy number alteration in uterine serous carcinoma and other types of 
gynecological neoplasia. Individual chromosomes (vertical axis) of each tumor 
(horizontal axis) are plotted using a pseudo-color gradient indicating the overall level of 
copy number alteration (low [black] to high [red]). Normal = normal tissue (n = 25); 
UEMC = uterine endometrioid carcinoma (n = 13); USC = uterine serous carcinoma (n = 
23); SBT = ovarian serous borderline tumor (n = 12); LGSC = ovarian low-grade serous 
carcinoma (n = 12); OEM = ovarian endometrioid carcinoma (n = 7); CCC = ovarian 
clear cell carcinoma (n = 12); HGSC = ovarian high-grade serous carcinoma (n = 33). 





Figure 2-3. Scatter plot of genome-wide chromosome instability index for individual 
tumors (open circles). Vertical blue lines indicate mean values; horizontal red lines 
indicate plus or minus one SD. 
 














USC 1.129 0.385 – .03 
HGSC 1.475 0.638 .03 – 
CCC 0.302 0.176 <.001 <.001 
LGSC 0.386 0.207 <.001 <.001 
OEM 0.228 0.220 <.001 <.001 
SBT 0.134 0.146 <.001 <.001 
UEMC 0.298 0.405 <.001 <.001 
*USC = uterine serous carcinoma; – = not applicable; HGSC = ovarian high-grade 
serous carcinoma; CCC = ovarian clear cell carcinoma; LGSC = ovarian low-
grade serous carcinoma; OEM = ovarian endometrioid carcinoma; SBT = ovarian 
serous borderline tumor; UEMC = uterine endometrioid carcinoma. 





2.2.4	  DNA	  Copy	  Number	  Alterations	  in	  Uterine	  Serous	  Carcinoma	  
We used DNAcopy and cghMCR software to identify genomic regions of uterine 
serous carcinomas that displayed a statistically significant copy number gain or loss 
compared with normal tissues. By using the mean SGOL score plus or minus 3 SDs to 
define amplified and deleted genes, respectively, we found 13 discrete amplified regions 
containing 307 genes and 25 discrete deleted regions containing 520 genes, including 25 
regions that harbored six or fewer genes. Frequently amplified genes (and the 
corresponding chromosomal locations) included BCL9 (1q21.1), EVI1 (3q26.2), KRAS 
(12p12.1), ADAM6 (14q32.33), and CCNE1 (19q12); the percentage of samples that 
exhibited an inferred gene copy number greater than three for BCL9, EVI1, KRAS, 
ADAM6, and CCNE1 were 13%, 21.7%, 4.4%, 30.4%, and 26.1%, respectively. Among 
these frequently amplified genes, the CCNE1 locus (chromosome 19: nucleotide 
34,995,401–35,007,059) demonstrated a very high SGOL score (9.1) and was amplified 
in six of the 23 uterine serous carcinoma samples examined (Figure 2-4 and 2-5). The 
most commonly deleted regions harbored LCE3C (1q21.3), MGAM (7q34), CSMD1 
(8p23.2), and CDH13 (16q23.3); these deletions occurred in 17.4%, 34.8%, 26.1%, and 








Figure 2-4. Overall view of DNA copy number gain and loss in uterine serous 
carcinoma. To generate an overview of DNA copy number alterations, we performed 
circular binary segmentation analysis and combined the segmentation results for all 23 
uterine serous carcinomas. Based on the Segments-of-Gain-Or-Loss (SGOL) scores 
(horizontal axis), DNA copy number gains (green) and losses (red) are plotted as a 
function of distance along the normal genome (vertical axis). Dashed vertical lines are 
generated based on the values of 3 SDs of the SGOL scores of gains or losses. Tumor-





Figure 2-5: Heat map of DNA copy number ratio along the chromosome 19. Arrow 
shows amplification in the CCNE1 locus in 23 uterine serous carcinoma samples. A = 
CCNE1 amplification; red circles = FBXW7 mutation; gray circle = FBXW7 hemizygous 
deletion. Suffix of the tumor numbers: TS and TCS = fresh tumor with affinity-purified 




To discover cancer-associated genes whose function was affected by somatic 
point mutation and DNA copy number change, we compared the genes that harbored 
nonsynonymous and splice site mutations (Appendix 1) with those that are amplified or 
deleted. This comparison yielded 11 genes, including BCL9, DAZAP1, and KRAS. In 
addition, close examination of copy number at the FBXW7 locus revealed that FBXW7 
was deleted in a hemizygous fashion in three tumors (Figure 2-6). This is interesting 
because FBXW7 encodes a substrate recognition component of a SKP1-cullin-F-box 
(SCF)–type E3 ubiquitin ligase, which is responsible for ubiquitin-dependent degradation 
of cyclin E (encoded by CCNE1). Thus, we examined the co-occurrence of somatic 
mutations and/or FBXW7 deletion and CCNE1 amplification in the 23 uterine serous 
carcinomas that were subjected to SNP array analysis. We found that seven tumors with 
FBXW7 mutations (four tumors with sequence mutations, three tumors with hemizygous 
deletions) did not have CCNE1 amplification, and six tumors with CCNE1 amplification 
did not have FBXW7 mutations; therefore, 13 (57%) of 23 tumors had either a molecular 
genetic alteration in FBXW7 or CCNE1 amplification (Figure 2-7). We also found that 
PIK3CA mutation and gene amplification were mutually exclusive except for one tumor 
(case ID: JB2411), which showed both genetic alterations. Integrated analysis 
demonstrated that 48% of the 23 uterine serous carcinomas harbored a PIK3CA mutation 
and/or PIK3CA amplification (Figure 2-7). Taken together, these findings suggest that the 








Figure 2-6. Heat map of the cancer-associated genes in COSMIC database with 
statistically significant DNA copy number variations (CNVs) from 23 uterine serous 
carcinomas. Pseudocolor gradient indicates the level of amplification (red) and deletion 









Figure 2-7. Molecular genetic alterations involving the FBXW7–cyclin E and 
phosphatidylinositol 3-kinase (PI3K) pathways in uterine serous carcinoma.A) Summary 





2.2.5	  FBXW7,	  PIK3CA,	  PPP2R1A,	  and	  TP53	  Mutations	  in	  
Serous	  Endometrial	  Intraepithelial	  Carcinoma	  
It has been proposed that serous endometrial intraepithelial carcinoma is the pre-
invasive precursor of uterine serous carcinoma (2,47,48). We, therefore, examined 
whether somatic mutations of the frequently mutated genes in uterine serous carcinoma 
identified in this study, including FBXW7, PIK3CA, PPP2R1A, and TP53, occurred in 
serous endometrial intraepithelial carcinoma. We identified nine uterine serous 
carcinomas that had a concurrent serous endometrial intraepithelial carcinoma 
component; we laser-capture microdissected nine serous endometrial intraepithelial 
carcinomas for mutation analysis. As summarized in Figure 2-8, all nine pairs of serous 
carcinoma and associated serous endometrial intraepithelial carcinoma had concordant 
PIK3CA, PPP2R1A, and TP53 mutation status between uterine serous carcinoma and its 
concurrent serous endometrial intraepithelial carcinoma component, whereas eight of the 
nine pairs had concordant FBXW7 mutation status between these two components. the 
only discordant pair (case ID: 1FFPE) contained a FBXW7 p.Asp440Asn mutation in the 
uterine serous carcinoma component, but this mutation was not detected in the serous 





Figure 2-8. Mutation profiles of FBXW7, PIK3CA, PPP2R1A, and TP53 in nine uterine 
serous carcinomas (USC) and with a concurrent serous endometrial intraepithelial 
carcinoma (SEIC) component. Manual microdissection and laser-capture microdissection 
were used to isolate USC and SEIC, respectively, for DNA analysis. Mutations are 
highlighted in different colors for each gene. ND = not done; wt = wildtype; NA = not 
available for analysis; *tumor (5FFPE) has two additional mutations in PIK3CA: S553Ifs, 




We also examined whether cyclin E protein expression, as detected by 
immunohistochemistry, was increased in FBXW7 mutated serous endometrial 
intraepithelial carcinomas. We found that all four pairs of serous endometrial 
intraepithelial carcinomas and concurrent serous carcinomas with a FBXW7 mutation had 
increased cyclin E expression compared with normal endometrial epithelium. The 
expression of cyclin E and FBXW7 mutation status in one of the cases are shown in 
Figure 2-9. The locations of FBXW7 mutations, including those found in five serous 
endometrial intraepithelial carcinomas and in 15 uterine serous carcinomas, are shown in 
Figure 2-10. All mutations were missense mutations except one (a splice site mutation) 
and were located in the WD40 domain. Our finding that most uterine serous carcinomas 
and their in situ counterparts have identical mutations, when taken together with previous 
reports (49,50) showing TP53 mutations in serous endometrial intraepithelial carcinoma, 
indicates that mutations in FBXW7, PIK3CA, PPP2R1A, and TP53 occur early during 





Figure 2-9. A uterine serous carcinoma (USC) with a serous endometrial carcinoma 
(SEIC) component. Top panel, SEIC; middle panel, USC. The tumor cells in both lesions 
show highly atypical and enlarged nuclei. The arrow indicates the junction between 
normal-appearing uterine surface epithelium (left) and SEIC (right). Cyclin E 
immunoreactivity (brown) was detected in both USC and SEIC cells but not in adjacent 
normal epithelium or stromal cells (scale bar = 100 um). Bottom panels: Mutational 
analysis showing an identical somatic mutation of FBXW7, from CGT to CAT (arrows), 









Figure 2-10. Locations of FBXW7 mutations identified among the 76 uterine serous 





This is the first study to our knowledge to characterize the genomic landscape of 
uterine serous carcinoma, a highly aggressive neoplastic disease in women. Whole-
exome sequencing and DNA copy number analysis demonstrated that mutations in TP53, 
PIK3CA, and FBXW7, as well as amplification of CCNE1, are the most common genetic 
alterations in this type of tumor. The presence of FBXW7 mutations and CCNE1 
amplification increased the levels of cyclin E protein, which facilitates cell cycle 
progression through cdk2, Rb phosphorylation, and E2F-1 (Figure 2-11). Conversely, an 
activating mutation and/or gene amplification of PIK3CA would enhance PI3K signaling 
and, subsequently, Akt activity, which promotes cellular proliferation and survival 
(Figure 2-11). Therefore, both signaling pathways may work in concert to promote 
tumorigenesis in uterine serous carcinoma. Because patients with uterine serous 
carcinoma are often diagnosed at late clinical stages when conventional chemotherapy is 
not effective, there is an unmet need to develop new therapeutics for those patients. The 
results as reported here suggest that PI3K inhibitors and inhibitors targeting the cyclin E 






Figure 2-11. Schematic presentation of possible mechanisms involving the FBXW7–
cyclin E and PI3K pathways in the development of uterine serous carcinoma. FBXW7 
gene deletion or mutation results in an increased level of cyclin E because of the 
suppression of FBXW7-mediated ubiqutination and subsequent proteasome-mediated 
degradation of cyclin E proteins. Alternatively, activation of PI3K can be a result of 
increased DNA copy number of PIK3CA and activating mutation of the gene. Increased 
E2F-1 and PI3K activity leads to activation of their downstream targets that promote cell 




Our results also have several biological implications regarding the molecular 
genetics of uterine serous carcinoma. First, this study not only confirmed frequent 
PIK3CA, PPP2R1A, and TP53 mutations in uterine serous carcinoma as previously 
reported (49,51-54) but also identified novel recurrent somatic mutations of FBXW7, 
which occurred in approximately 20% of tumors. Although FBXW7 mutations have been 
reported in several types of human cancers, including those of hematopoietic, 
gastrointestinal tract, pancreatic, uterine, and cervical origins (55), to our knowledge, this 
gene has not been sequenced in uterine serous carcinoma. FBXW7, also known as 
hCDC4, is a member of the F-box family of proteins that serves as a substrate recognition 
component of the ubiquitin ligase SCF complex (55,56). FBXW7 functions as a 
haploinsufficient tumor suppressor gene (57), and the protein is responsible for the 
ubiquitin-dependent proteolysis of several tumor-promoting proteins, including cyclin E, 
c-Jun, c-Myc, MCL1, and Notch (56,58-62). It is interesting that our DNA copy number 
analysis revealed that the CCNE1 locus is one of the most frequently amplified 
chromosomal regions in uterine serous carcinoma and that CCNE1 amplification occurs 
mutually exclusively with FBXW7 mutations (including point mutation and deletion), 
suggesting that CCNE1 and FBXW7 participate in the same signaling pathway. In fact, 
we found that molecular genetic aberrations in the cyclin E pathway due to FBXW7 point 
mutations, FBXW7 deletions, or CCNE1 amplification, when considered together, 
occurred in more than half of uterine serous carcinomas. Thus, activation of cyclin E, 
either by inhibiting its ubiquitin-dependent protein degradation due to FBXW7 mutations 
or by increased expression as a result of gene amplification, may play a major role in 




Second, we observed that concordant mutation status in PIK3CA, PPP2R1A, and 
TP53 occurred in all nine pairs of tumors containing uterine serous carcinoma and 
concurrent serous endometrial intraepithelial carcinoma, whereas concordant FBXW7 
mutation status was found in eight of nine pairs. This result suggests that mutations of the 
above genes occurred in the pre-invasive stage of uterine serous carcinoma and, if 
confirmed in a larger number of tumors, may have translational implications. For 
example, detection of those mutations may be helpful for screening for uterine serous 
carcinoma at a preinvasive stage in endometrial curettage or cervical lavage specimens 
using emerging highly sensitive molecular techniques. 
Third, our results may clarify the relationship between uterine serous carcinoma 
and ovarian high-grade serous carcinoma, another highly aggressive gynecologic 
neoplasm. these two tumors have different clinicopathologic features, such as older age at 
diagnosis for uterine serous carcinoma compared with ovarian high-grade serous 
carcinoma [68 years for uterine serous carcinoma vs. 55 years for ovarian high-grade 
serous carcinoma (2)] and a genetic predisposition for some cases of ovarian serous 
carcinoma due to germline BRCA1 and BRCA2 mutations (2) but not for uterine serous 
carcinoma. however, uterine serous carcinoma and ovarian high-grade serous carcinoma 
have some similar features, including an aggressive clinical course, certain morphological 
features, and a similar relationship to intraepithelial carcinoma precursors (2). 
Molecularly, both are characterized by a high prevalence of TP53 mutations, a similar 
overall number of somatic mutations, and a high level of genome-wide DNA copy 
number alterations. In fact, in the World health organization histopathologic classification 




share similar morphological features. However, in this study, we found a higher 
frequency of somatic mutations in FBXW7, PIK3CA, and PPP2R1A in uterine serous 
carcinoma compared with ovarian high-grade serous carcinoma, providing evidence for 
molecular genetic alterations that are unique to uterine serous carcinoma. 
There are two major limitations in this study. First, we focused on only 10 uterine 
serous carcinomas in the discovery set, and it is possible that other somatic genetic 
changes will be identified in studies using a larger cohort. Second, we did not investigate 
whether the molecular changes reported here are associated with any clinical features. 
Therefore, it will be interesting to determine whether mutations in FBXW7, PIK3CA, 
PPP2R1A, or TP53 are associated with clinical stage, disease-free or overall survival, or 
response to treatment. 
In summary, genome-wide analyses identified aberrations involving three 
pathways, the p53, PI3K, and cyclin E–FBXW7 pathways, in uterine serous carcinomas. 
Our findings have important implications not only for understanding the pathogenesis of 
uterine serous carcinoma but possibly also for developing more effective target-based 
therapy. Moreover, the presence of these changes in the preinvasive stage of uterine 
serous carcinoma suggests that these molecular alterations occur relatively early in tumor 
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3	  TERT	  Promoter	  Mutation	  in	  
Gynecological	  Malignancies	  
 
Telomeres are DNA–protein complexes that protect the ends of eukaryotic 
chromosomes by preventing them from being recognized as DNA double-strand breaks, 
which inappropriately trigger DNA damage response pathways and may lead to cellular 
senescence or illegitimate fusion of chromosomal ends (64). The termini of a linear DNA 
template cannot be completely replicated by conventional DNA-dependent DNA 
polymerases and thus, in the absence of mechanisms to counter this effect, telomeres of 
eukaryotic cells shorten every round of DNA replication. Telomere shortening in somatic 
cells limits the life span of somatic cells and acts as a natural barrier to oncogenic 
transformation (65). To maintain unlimited replication potential, cancer cells evolve 
mechanisms to maintain telomere length (11). Most cancers, especially carcinomas, 
maintain their telomere length by increasing the activity of telomerase reverse 
transcriptase (TERT), the catalytic unit of the telomerase that adds the six-nucleotide 
telomere sequences to the end of chromosomes (12). This is made possible through a 
variety of mechanisms, including amplification of the TERT gene (13), expression of 
transcriptional activators of TERT (14) and CpG methylation at the TERT promoter (15). 
Some cancers maintain telomere length through a telomerase-independent mechanism 




homologous recombination (67). 
Recently, somatic mutations at the TERT promoter in human cancer have been 
reported in two independent studies, using whole-genome sequencing on sporadic 
melanomas and multipoint linkage analysis in melanoma-prone families (16,17). Both 
studies demonstrated an unusually high frequency of TERT promoter mutations in 
sporadic melanomas; >70% of cases studied harboured such mutations (16,17). 
Subsequent studies reported TERT promoter mutations in other malignancies, including 
glioma, urinary bladder carcinoma, tongue squamous cell carcinoma and hepatocellular 
carcinoma (18-20). The majority of reported mutations are located at two hot-spots, both 
of which create an 11 bp sequence, resembling the binding motif for ETS-domain 
transcription factors (16,17). Mutations in these hot-spots were shown to enhance 
transcriptional activity of the TERT promoter in vitro, and were thought to increase the 
expression of TERT in cancer cells (17). 
Cancer genomes have been recently sequenced in a number of gynecological 
neoplasms, including high-grade ovarian serous carcinoma, low-grade ovarian serous 
carcinoma, ovarian clear cell carcinoma, uterine endometrioid carcinoma and uterine 
serous carcinoma (23,24,37,68,69). However, the prevalence and clinical significance of 
TERT promoter mutations in gynecological malignancies remains largely unclear because 
noncoding regions, including promoter sequences, were not routinely included in the 
previous analyses. In this study, we analyzed TERT promoter mutations in a total of 525 
gynecological malignancies, and evaluated the biological and clinical significance of 






3.1.1	  Screening	  TERT	  promoter	  mutations	  in	  gynecological	  
A total of 250 anonymous fresh-frozen tissues were obtained from the Johns 
Hopkins Hospital (Baltimore, MD, USA) and 275 anonymous formalin-fixed paraffin-
embedded (FFPE) tissues were obtained from Asan Medical Centre (Seoul, Korea), 
National Taiwan University Hospital (Taipei, Taiwan), Seirei Mikatahara General 
Hospital (Hamamatsu, Japan), Toronto General Hospital (Toronto, Canada) and 
University of Tokyo Hospital (Tokyo, Japan). All samples were procured under 
appropriate approval of institutional review boards. Haematoxylin and eosin (H&E)-
stained sections were re-reviewed by pathologists (RC, AA and IS) to confirm the 
diagnosis before experiments. Genomic DNA from frozen tissue was extracted by the 
DNeasy blood and tissue kit (Qiagen, Valencia, CA, USA). For FFPE tissues, tumor 
components were manually dissected from 10 µm sections to reduce normal tissue 
contamination. Genomic DNA of dissected tumor tissue was then extracted using the 
QIAmp DNA FFPE tissue kit (Qiagen). We obtained genomic DNA from a total of 525 
gynecological malignancies, including 389 ovarian carcinomas, 58 uterine corpus 
malignancies and 78 uterine cervical carcinomas. More specifically, the ovarian 
carcinomas included 233 clear cell carcinomas (36 fresh-frozen and 197 FFPE), 43 
endometrioid carcinomas (fresh-frozen), 80 high-grade serous carcinomas (fresh-frozen) 
and 33 low-grade serous carcinomas (fresh-frozen). The uterine corpus malignancies 




carcinomas (fresh-frozen) and 22 leiomyosarcomas (fresh-frozen). The uterine cervical 
carcinomas included 53 squamous carcinomas (FFPE) and 25 endocervical 
adenocarcinomas (FFPE). The sources and types of each tissue specimen are specified in 
the supplementary material (Appendix 3). 
The TERT promoter region containing the two mutation hot-spots (chr5: 1 295 
228 and 1 295 250; hg19) were amplified by polymerase chain reaction (PCR), using the 
following primers: 5′-M13-CAGCGC TGCCTGAAACTC-3′ and 5′-
GTCCTGCCCCTTCAC CTT-3′, where M13 is a universal sequencing primer with 
sequence 5′-GTAAAACGACGGCCAGT-3′. PCR was performed using the following 
conditions: 94◦C for 2 min; three cycles at 94◦C for 15 s, 64◦C for 30 s and 70◦C for 30 s; 
three cycles at 94◦C for 15 s, 61◦C for 30 s and 70◦C for 30 s; three cycles at 94◦C for 15 
s, 58◦C for 30 s and 70◦C for 30 s; and 30 cycles at 94◦C for 15 s, 57◦C for 30 s and 70◦C 
for 30 s, followed by 70◦C for 5 min. Sanger DNA sequencing was performed by either 
Macrogen (Rockville, MD, USA) or Beckman Coulter Genomics (Danvers, MA, USA). 
Mutational analysis was performed using a software package (Mutation Surveyor 4.0; 






3.1.2	  TERT	  promoter	  mutation	  in	  precursor	  lesions	  of	  ovarian	  clear	  
cell	  carcinoma	  
Nine ovarian clear cell carcinomas with TERT promoter mutations contained 
normal-appearing or atypical endometriotic cyst epithelium adjacent to the carcinoma. 
The cyst epithelium was carefully microdissected with 27-gauge needles and the genomic 
DNA of dissected tissue was then extracted using the QIAmp DNA FFPE tissue kit 
(Qiagen). TERT promoter sequences were analyzed separately for matched samples of 
clear cell carcinoma and adjacent normal/atypical cystic epithelium. 
 
3.1.3	  TERT	  promoter	  mutation	  and	  mRNA	  expression	  in	  ovarian	  
clear	  cell	  carcinoma	  
Cell lines derived from ovarian clear cell carcinomas were cultured in RPMI 1640 
medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (FBS; Atlanta Biological, Lawrenceville, GA, USA) (JHOC5, KK, KOC-7C, 
OVCA429, OVISE, and OVTOKO) or Dulbecco's modified Eagle's medium (DMEM; 
Life Technologies) supplemented with 10% FBS (OV207, ES-2 and TOV21G). Genomic 
DNA was isolated from cell lines using the DNeasy blood and tissue kit (Qiagen) and 
RNA was extracted using the RNeasy blood and tissue kit (Qiagen). The TERT promoter 
region was amplified and sequenced and quantitative reverse-transcription PCR was 




SYBR green qPCR master mix (Thermo Fisher Scientific, Waltham, MA, USA) and 500 
nM primers. The TERT primers used were: 5′-CAGGATCTCCTCACGCAGAC-3′ and 
5′GAGCTGACGTGGAAGATGAG-3′. APP was used as an internal expression control 
because of its stable expression among ovarian cancers. The APP primers used were: 5′-
CTGAAGATGGATGCAGAATTCC-3′ and 5′-AAAGAACTTGTAGGTTGGATTT-3′. 
 
3.1.4	  Telomere	  length	  evaluation	  in	  ovarian	  clear	  cell	  carcinoma	  
Telomere length in ovarian clear cell carcinoma was assessed in our previous 
study (70) by telomere fluorescence in situ hybridization; 32 ovarian clear cell 
carcinomas from this previous cohort had quality DNA available for sequencing analysis 
and were included in the current study. The mean relative telomere length of carcinoma 
cells normalized to telomere length of stromal cells was calculated as the telomere index 
(70). Telomere indices were compared between ovarian clear cell carcinomas with TERT 
promoter mutation and those without. 
 
3.1.5	  Immunohistochemical	  staining	  for	  ARID1A	  in	  ovarian	  
Immunohistochemistry for ARID1A was performed on a total of 191 ovarian 
clear cell carcinoma samples. Among them, 99 cases had been previously stained and 




additional cases were analyzed in this report. Immunohistochemical staining for ARID1A 
was performed using the following protocol. Antigen retrieval was performed on 
rehydrated tissue sections in a pH 6.0 citrate buffer (Dako, Carpinteria, CA, USA) at 
92◦C for 30 min. The sections were incubated overnight at 4◦C with a rabbit polyclonal 
antiARID1A antibody (HPA005456, Sigma-Aldrich) at a dilution of 1:1000, and 
visualized by the EnVision+ System (Dako). For each section, only nuclear staining was 
scored and positive nuclear staining in stromal cells was used as positive control. The 
tissues were examined in a blinded fashion without knowledge of clinical information or 
TERT mutation status. 
 
3.1.6	  Sequencing	  of	  PIK3CA	  in	  ovarian	  clear	  cell	  carcinoma	  
Of the ovarian clear cell carcinoma samples in this study, 45 have been previously 
sequenced for PIK3CA (73). An additional 35 ovarian clear cell carcinomas were 
sequenced for PIK3CA (coding exons 1, 9 and 20), following the afore-mentioned 
protocol. The amplification primers used for PIK3CA sequencing were as follows: 
proximal coding exon 1, 5′-TGCTTTGGGACAACCATACATC-3′ and 
5′CTTGCTTCTTTAAATAGTTCATGCTTT-3′; distal coding exon 1, 5′-
CCCCTCCATCAACTTCTTCAA-3′ and 5′-ATTGTATCATACCAATTTCTCGATTG-
3′; coding exon 9, 5′-TTTTCTGTAAATCATCTGTGAAT CC-3′ and 5′-




CCAAACTGACCAAAC-3′ and 5′-ACTCCAAAGC CTCTTGCTCA-3′; distal coding 
exon 20, 5′-ACATT CGAAAGACCCTAGCC-3′ and 5′-M13-GGTCTTTG 
CCTGCTGAGAGT-3′. The sequencing primers for PIK3CA were as follows: proximal 
coding exon 1, 5′-ACCATCATCAGGTGAACTGTGG-3′; distal coding exon 1, 5′-
CTCAAGAAGCAGAAAGGGAAG-3′; coding exon 9, 5′-
AAAATATGACAAAGAAAGCTATAT -3′ ; proximal and distal coding exon 20, 5′-
GTAAAACGACGGCCAGT-3′ (M13). 
 
3.1.7	  Statistical	  analysis	  
Two-tailed Fisher's exact test and unpaired t-test were performed to determine the 
association between mutation status at the TERT promoter and clinicopathological 
features in ovarian clear cell carcinoma. Confidence intervals of mutation frequencies 
were determined using the Agresti–Coull method, and mutation frequencies of different 
cancer types were compared using two-tailed Fisher's exact test. Disease-specific overall 
survival of ovarian clear cell carcinoma, with and without TERT promoter mutations, was 
compared using the Kaplan–Meier method, followed by the log-rank test to determine 
significance. Comparison of TERT mRNA expression levels between mutant and wild-
type ovarian clear cell carcinoma cell lines was performed using one-tailed Mann – 
Whitney U-test to determine whether TERT promoter mutation was associated with 




and wild-type ovarian clear cell carcinomas, one-tailed Mann – Whitney U-test was used 
when the telomere index was treated as a continuous variable, and Fisher's exact test was 
used when the telomere index was treated as a binary variable. Two-tailed Fisher's exact 
test was used to determine the association between TERT promoter mutation and loss of 
ARID1A immunoreactivity, as well as the association between TERT promoter mutation 
and PIK3CA mutation in ovarian clear cell carcinoma. p < 0.05 was considered 






3.2.1	  TERT	  promoter	  mutations	  in	  gynecological	  malignancies	  
Sequencing analysis was performed in the TERT promoter region containing the 
two previously reported mutation hot-spots. The frequencies of TERT promoter mutations 
in various gynecological cancers are summarized in Table 3-1. TERT promoter mutations 
were detected in 40 of 525 tumor samples (7.6%; 95% CI 5.6–10.2%), the majority 
occurring in ovarian clear cell carcinomas. While present in only three of 292 other 
tumors (1.0%; 95% CI: 0.2–3.1%), 37 of 233 (15.9%; 95% CI 11.7–21.2%) ovarian clear 
cell carcinoma specimens harbored TERT promoter mutations. The difference in mutation 
frequency was significant between clear cell carcinoma and other gynecological 
neoplasms (p < 0.0001, two-tailed Fisher's exact test). Among the 40 mutations, 37 were 
located at –124 bp from the TERT translation start site, while only three were at –146 bp 
(Figure 3-1). Since ovarian clear cell carcinoma and endometrioid carcinoma are thought 
to arise from endometriotic cysts (endometriomas) (74), we compared the TERT promoter 
mutation frequency between these two cancer types, and found a significantly higher 
frequency of TERT promoter mutation in ovarian clear cell carcinoma than in ovarian 
endometrioid carcinoma (p = 0.0024, two-tailed Fisher's exact test). There was no 
significant difference in TERT promoter mutation frequency among the ovarian clear cell 
carcinoma samples collected from different institutions (p = 0.3137, Fisher's exact test) or 





Table 3-1. Prevalence of TERT promoter mutation in gynecologic malignancies 
  
   mutated/total percentage Specific mutations * 
Ovarian Cancers    
clear cell carcinoma 
        clinical sample 








c.-124C>T (n=34); c.-146C>T (n=3) 
c.-124C>T(n=2); c.[-138C>T;-139C>T]**(n=1) 
endometrioid carcinoma 0/43 0.0%  
high-grade serous carcinoma 0/80 0.0%  
low-grade serous carcinoma 1/33 3.3% c.-124C>T (n=1) 
Uterine Corpus Cancers    
endometrioid carcinoma 0/24 0.0%  
serous carcinoma 0/12 0.0%  
leiomyosarcoma  0/22 0.0%  
Uterine Cervix Cancer    
squamous cell carcinoma 2/53 3.7% c.-124C>T (n=2) 
         endocervical adenocarcinoma 0/25 0.0%  







Figure 3-1. TERT promoter mutations in ovarian clear cell carcinoma. Shown are 
representative chromatograms of the wild-type TERT promoter and two mutated TERT 








3.2.2	  TERT	  promoter	  mutations	  are	  not	  present	  in	  endometriotic	  
cyst	  epithelium	  adjacent	  to	  ovarian	  clear	  cell	  carcinoma	  
To determine whether TERT promoter mutation occurs early in the development 
of clear cell carcinoma, we analyzed nine ovarian clear cell carcinomas with TERT 
promoter mutations in which there was sufficient endometriotic cyst epithelium for 
mutational analysis. TERT promoter mutations were not identified in any of the nine 
specimens (Figure 3-2). This finding suggests that TERT promoter mutations do not 
occur early in the tumor progression from endometriotic cyst to clear cell carcinoma. 
 
Figure 3-2. An example of ovarian clear cell carcinoma arising from an endometriotic 
cyst. TERT promoter mutation occurred in clear cell carcinoma but not in the adjacent 




3.2.3	  TERT	  promoter	  mutation	  is	  associated	  
with	  elevated	  mRNA	  expression	  in	  ovarian	  clear	  cell	  carcinoma	  cell	  
lines	  
In a screen of nine ovarian clear cell carcinoma cell lines, we found that three 
(33.3%; 95% CI 11.7 – 64.9%) contained mutations at the TERT promoter. Cell lines 
JHOC5 and OV207 carried the hot-spot mutation c.–124C>T, whereas the ES-2 cell line 
harbored the less common tandem mutation c.[ – 139C>T; – 138C>T], which has been 
reported in a few melanomas (16). Cell lines harboring the c.–124C>T mutation showed 
a five to eight-fold increase of TERT mRNA expression as compared to the cell lines 
without TERT promoter mutation (Figure 1c). Overall, clear cell carcinoma cell lines with 
TERT promoter mutations expressed higher levels of TERT mRNA than those with wild-
type sequence (p = 0.0238, one-tailed Mann – Whitney U-test; Figure 3-3). 
 
Figure 3-3. Ovarian clear cell 
carcinoma cell lines with mutated 
TERT promoter have increased 
expression of TERT mRNA. Red 
circles: OV207 and JHOC5 cells with 
c.-124C>T mutation; blue circle: ES-2 
cell with c.[-139C>T;-138C>T] tandem 
mutation; black horizontal bar: mean; 




3.2.4	  Ovarian	  clear	  cell	  carcinomas	  with	  TERT	  promoter	  mutation	  
tend	  to	  have	  longer	  telomere	  length	  
In a previous study (70), we assessed the telomere length in different types of 
ovarian carcinomas and found that clear cell carcinoma had the longest average telomere 
length compared to other histological types of ovarian carcinomas. To examine the 
relationship between TERT promoter mutation and telomere length, we compared TERT 
promoter mutation status and telomere length data in 32 ovarian clear cell carcinomas, 
including six with TERT promoter mutations and 26 without. There was a trend towards 
longer telomere length in ovarian clear cell carcinomas with TERT promoter mutation 
relative to those without, although statistical significance was not reached (median 1.1 
versus 0.36; p = 0.2278, one-tailed Mann-Whitney U test; Figure 3-4). Similarly, when 
telomere length was coded as a binary variable (telomere index >1 versus ≤1), clear cell 
carcinomas with TERT promoter mutation showed higher, although not statistically 
significant, frequency of possessing long telomere length (index >1) than those without 
TERT promoter mutation (3/6 versus 3/26; p = 0.0629, Fisher's exact test; Figure 3-4). 
Figure 3-4. Comparison of telomere 
length between ovarian clear cell 
carcinomas with and without TERT 
promoter mutation. Black horizontal bar: 
mean; error bar: SEM; gray horizontal 




3.2.5	  TERT	  promoter	  mutation	  is	  inversely	  associated	  with	  loss	  of	  
ARID1A	  protein	  expression	  in	  ovarian	  clear	  cell	  carcinomas	  
ARID1A, a tumor suppressor gene, is the most frequently mutated gene in ovarian 
clear cell carcinoma (23,75). It has been shown that loss of ARID1A expression is a 
surrogate marker for its mutation (71). To examine the correlation between TERT 
promoter mutation and ARID1A aberration, we compared the TERT promoter mutation 
status and ARID1A protein expression data in 191 of the analyzed ovarian clear cell 
carcinomas. Loss of ARID1A protein expression was detected by immunohistochemistry 
in 115/191 (60.4%) ovarian clear cell carcinoma samples: in four of 31 (12.9%) cases 
harboring the TERT promoter mutation compared to 111 of 160 (69.4%) cases without 
(Table 3-2). This result indicates a strong tendency towards mutual exclusivity between 
TERT promoter mutation and lack of ARID1A expression (odds ratio = 0.066, p = 4.4 × 
10–9, two-tailed Fisher's exact test). 
 
 
Table 3-2. Correlation between TERT promoter mutation and ARID1A immunoreactivity 





3.2.6	  TERT	  promoter	  mutation	  and	  PIK3CA	  mutation	  tend	  to	  be	  
mutually	  exclusive	  in	  ovarian	  clear	  cell	  carcinoma	  
PIK3CA is the second most commonly mutated gene in ovarian clear cell 
carcinoma (73). To determine the correlation between TERT promoter mutation and 
PIK3CA mutation, we sequenced PIK3CA hot-spot coding exons 1, 9 and 20 for 80 
ovarian clear cell carcinomas, 45 of which, including nine ovarian clear cell carcinoma 
cell lines, had been reported previously (73). Interestingly, we observed a strong 
tendency towards mutual exclusivity between TERT promoter and PIK3CA mutations 
(odds ratio = 0.074; p = 0.0019, two-tailed Fisher's exact test), with only one of the 80 
samples harboring both TERT promoter and PIK3CA mutations (Table 3-3). All clinical 
samples that had PIK3CA mutation, TERT promoter mutation and ARID1A 
immunostaining data (n = 71) are summarized in Figure 3-5. 
 
 
Table 3-3. Correlation between TERT promoter mutation and PIK3CA mutation in 








Figure 3-5. Mutation status of TERT promoter and PIK3CA, and immunostaining result of ARID1A in 71 clear cell carcinoma tissues. 





3.2.7	  TERT	  promoter	  mutation	  has	  no	  impact	  on	  prognosis	  in	  
ovarian	  clear	  cell	  carcinoma	  
Next, we determined correlations between TERT promoter mutation status and 
clinicopathological features of ovarian clear cell carcinoma (Table 3-4). We found no 
association between TERT promoter mutation and patients' age, FIGO stage, lymph node 
metastasis, nuclear atypia and histological features. In 196 ovarian clear cell carcinomas 
with available survival data, there was no significant difference in disease-specific overall 
survival between patients with TERT promoter mutations and those without (hazard ratio 
0.9790; 95% CI 0.4347–2.205; p = 0.9592, log-rank test; Figure 3-6). 
 
Table 3-4. Clinicopathological features of ovarian clear cell carcinoma 
 Mutant Wild-type P value 
Age (n = 196)    
        mean ± SD 51.6 ± 10.4 51.8 ± 9.3 0.9106 
        median 52 51  
        range 33-73 25-76  
FIGO stage (n = 175)   
          I / II 22 112 1.0000 
        III / IV 7 34  
Lymph node metastasis (n = 88)  
        positive 0 15 0.1992 
        negative 11 62  
Nuclear atypia (n = 83)   
        mild 3 25 0.8999 
        moderate 5 33  
        severe 1 16  
Predominant histological pattern (n = 83)  




        tubulocystic 3 21  




Figure 3-6. Kaplan-Meier survival curves of ovarian clear cell carcinoma patients. 







In this study, we found that among all types of gynecological cancers examined, 
ovarian clear cell carcinomas had the highest frequency of TERT mutations. Ovarian 
clear cell carcinoma is a unique type of ovarian cancer and advanced stage clear cell 
carcinoma is associated with a poorer prognosis because the tumor is resistant to 
platinum-based chemotherapy (76). Ovarian clear cell carcinoma has been thought to 
develop from endometriotic cyst (endometrioma) of the ovary, which has also been 
considered a precursor lesion of ovarian endometrioid carcinoma (74). Ovarian clear cell 
carcinoma and endometrioid carcinoma share several molecular genetic alterations, 
including activating mutations in PIK3CA and inactivating mutations and loss of 
expression in ARID1A and PTEN (73,75). Despite these similarities, ovarian clear cell 
carcinoma, as compared to ovarian endometrioid carcinoma, is characterized by distinct 
molecular features, including up-regulation of hepatocyte nuclear factor-1β and less 
frequent mutation in CTNNB1 (68,73,77). The higher mutation frequency in TERT 
promoters, as reported here, underscores the difference in the pathogenesis of ovarian 
clear cell carcinoma and ovarian endometrioid carcinoma. 
Analysis of the mutation types reveals the likely mechanism by which TERT 
promoter mutations contribute to tumor development. Both hot-spot mutations (c. – 
124C>T and c. – 146C>T) at the TERT promoter create an 11 bp sequence that contains 
the binding motif (CCGGAA) of ETS-domain transcription factor family members, and 
both mutations have been shown to increase transcriptional activity of the TERT promoter 




with higher TERT mRNA expression in the ovarian clear cell carcinoma cell lines 
examined. The less common tandem mutation c.[ – 139C>T; – 138C>T] also generates 
an ETS binding motif. ETS-domain transcription factors act as activators or repressors of 
a compendium of genes that are involved in diverse biological processes, many of which 
are cancer-related, including cellular proliferation, inhibition of apoptosis, regulation of 
cellular senescence and angiogenesis (78). Abnormalities of ETS-domain family 
members have been implicated in a variety of human cancers through different 
mechanisms, including amplification, mutation, and translocation that generates fusion 
proteins (79). In addition, several ETS-domain transcription factors are activated by 
mitogen-activated protein kinase (MAPK), which is commonly up-regulated in cancer 
cells (78). Since all hot-spot mutations result in the creation of a new ETS-binding motif 
that is accessible to ETS factors, it is likely that these mutations turn the TERT promoter 
into a target of ETS-domain transcription factors. 
Several molecular genetic abnormalities, including ARID1A mutation, PIK3CA 
mutation and PTEN deletion (loss of heterozygosity), have been thought to be early 
events in the development of ovarian clear cell carcinoma, as these alterations are 
frequently detected in both carcinoma and adjacent benign epithelium within the 
endometriotic cyst, the precursor lesion of ovarian clear cell carcinoma (72,80-82). In this 
study, we did not detect TERT promoter mutations in the contiguous endometriotic cyst 
epithelium associated with ovarian clear cell carcinomas that harbored TERT promoter 
mutations. This result indicates that TERT promoter mutation is unlikely to be an early 
event in tumorigenesis. This finding can be explained by the telomere crisis theory during 




gradually acquiring somatic mutations, until they reach a sufficient number of cell 
divisions, when accumulated telomere erosion triggers senescence and/or deleterious 
genomic instability. Therefore, in order to survive, pre-cancer cells need to develop a 
strategy to escape from telomere crisis. TERT promoter mutation is dispensable during 
the very early stage of tumor initiation because it does not provide a survival advantage 
until telomere attrition becomes evident. During the telomere crisis stage, only the cells 
that acquire the ability to maintain telomere length through ways such as TERT promoter 
mutation will progress through this selection pressure. 
Recent genome-wide analysis has revealed that ARID1A, a tumor suppressor 
gene, is the most frequently mutated gene in ovarian clear cell carcinoma; somatic 
mutation of ARID1A was found in approximately half of ovarian clear cell carcinomas 
(23,75). Because ARID1A mutations correlate with loss of expression, 
immunohistochemistry has been used to assess ARID1A mutation status on tissue sections 
(71). In this study, we found that TERT promoter mutation was inversely associated with 
loss of ARID1A protein expression (presumably through mutations) in ovarian clear cell 
carcinoma. This implies that intact ARID1A-containing BAF chromatin remodeling 
complexes may be required for TERT re-expression mediated by a mutated TERT 
promoter. Alternatively, loss of ARID1A may facilitate incipient tumor cells to achieve 
replicative immortality. Thus, it is not essential for those tumor cells to acquire TERT 
promoter mutation. 
PIK3CA, an oncogene, was found to be mutated in about one-third of ovarian 
clear cell carcinomas (73). Interestingly, in this study, we demonstrated that TERT 




exclusivity in 80 ovarian clear cell carcinoma samples examined. The PI3K/AKT 
signaling pathway plays a role in maintaining self-renewal in embryonic stem cells (85) 
and cancer stem cells (86-89). Moreover, the PI3K/AKT pathway is involved in 
transcriptional up-regulation of TERT and activation of telomerase through 
phosphorylation (90-93). Therefore, like TERT promoter mutation, activating PIK3CA 
mutation confers a growth advantage upon cancer cells by overcoming the hurdle of 
replicative senescence. Consequently, TERT promoter mutation is not selected in ovarian 
clear cell carcinomas with PIK3CA mutations. 
Ovarian clear cell carcinoma patients with TERT promoter mutation have no 
difference in disease specific overall survival as compared to those without TERT 
promoter mutation. This finding contrasts with a previous study, in which primary 
gliobastoma with TERT promoter mutations had a worse prognosis than patients without 
TERT mutations (18). We note that most glioblastomas that do not have TERT promoter 
mutations exhibit the alternative lengthening of telomere (ALT) phenotype, which has 
been reported as an independent indicator of better prognosis (94), whereas only a small 
proportion of ovarian clear cell carcinomas exhibit the ATL phenotype (66). Therefore, 
the discrepancy is not surprising. To learn more about the effect of TERT promoter 
mutation on patients' outcome, it would be helpful to compare the prognosis between 
TERT promoter mutants and wild-types in other cancers in which ALT is uncommon, 
such as hepatocellular carcinomas, urothelial carcinomas or squamous cell carcinomas of 
the tongue (18,19,66). 
In summary, we found that TERT promoter mutations were most common in 




mutation was associated with higher TERT mRNA levels in ovarian clear cell carcinoma 
cell lines. TERT promoter mutation showed strong tendency towards mutual exclusivity 
with loss of ARID1A expression and PIK3CA mutation in ovarian clear cell carcinoma. 
These results, in conjunction with our previous report showing longer telomeres in 
ovarian clear cell carcinomas compared to other types of ovarian cancer, suggest an 
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4	  Conclusions	  	  
To our knowledge, the integrative genomic analysis presented here is the first one 
trying to portray the genomic landscape of uterine serous carcinoma. We demonstrated 
that mutations in TP53, PIK3CA, FBXW7, and PPP2R1A, as well as amplification of 
CCNE1, are the most common genetic aberrations in this type of cancer. Both FBXW7 
mutation and CCNE1 amplification, being mutually exclusive events and affecting more 
than half of uterine serous carcinomas, increase the expression of cyclin E protein, which 
facilitates cell cycle progression. On the other hand, activating mutation and/or 
amplification of PIK3CA, together affecting 48% of uterine serous carcinoma, enhance 
PI3K signaling pathway and subsequently, AKT activity, which promotes cellular 
proliferation and survival. Both PI3K and cyclin-E/FBXW7 pathways are likely work in 
concert to promote tumorigenesis in uterine serous carcinoma. These results suggest that 
inhibitors targeting PI3K or cyclin E pathways are potentially effective treatments against 
uterine serous carcinoma, especially at advanced-stage when the conventional 
chemotherapy is often not effective. 
 In this study, we also showed that the mutations in FBXW7, PIK3CA, PPP2R1A, 
and TP53 are almost always concordant between uterine serous carcinoma and its 
precursor, serous endometrial intraepithelial carcinoma. This result indicates that  
mutations of these genes occurred before the in-situ carcinomas turn into invasive ones. 




screening mutations in these genes can be used for early diagnosis of uterine serous 
carcinoma at a preinvasive stage in endometrial curettage or cervical lavage specimens 
using emerging molecular techniques that are highly sensitive. 
In the second study, I discovered that ovarian clear cell carcinoma has a high 
frequency of TERT promoter mutations, a characteristic not shared by other major 
subtypes of gynecologic cancers, including ovarian endometrioid carcinoma. Ovarian 
endometrioid carcinoma bears a strong resemblance to ovarian clear cell carcinoma: they 
are both thought to develop from endometriotic cyst of the ovary (74); they share several 
molecular genetic features, with PI3K and ARID1A the two most commonly deregulated 
pathways in both carcinomas (73,75). Our discovery of higher mutation frequency in 
TERT promoter in clear cell carcinoma highlights the difference in the pathogenesis of 
these two carcinomas. Moreover, this molecular genetic attribute has the potential to 
serve as a useful biomarker for differential diagnosis between ovarian clear cell 
carcinoma and other subtypes of ovarian cancers, and may have an impact on 
personalized cancer management if small molecules targeting the TERT promoter 
function are developed in the future.  
Almost all the TERT promoter mutations detected are confined to two hot-spots, 
both creating an 11-bp sequence that contains the binding motif of ETS-domain 
transcription factors. The promoter mutations are associated with higher TERT 
transcriptional activity. It is likely that the hot-spot mutations make the TERT promoter 
accessible to ETS-domain transcription factors, thereby inducing TERT mRNA 
transcription. A deeper investigation into the potential interaction between the mutated 




specific therapeutic target. 
ARID1A, encoding a subunit of the SWI/SNF chromatin remodeling complex, is 
mutated in about half of ovarian clear cell carcinomas (23,75). In this study, we found 
that TERT promoter mutations tend to be mutually exclusive with loss of ARID1A 
expression. This is a clue suggesting that ARID1A may play a role in telomere biology. 
One explanation is that ARID1A-containing SWI/SNF chromatin remodeling complexes 
may be required for TERT re-expression mediated by a mutated TERT promoter. Hence, 
the cancer cells without functioning ARID1A cannot employ TERT promoter mutation as 
a strategy to re-activate telomerase expression. Alternatively, loss of ARID1A may 
facilitate incipient tumor cells to overcome replicative senescence. Thus, it is not 
essential for tumor cells with ARID1A mutation to acquire TERT promoter mutation. 
Future work should focus on answering whether and how ARID1A actually works to 
regulate telomere homeostasis. 
In summary, our study of the genome of uterine serous carcinoma identified the 
major genetic culprits in the development of this tumor: p53, cyclin E-FBXW7, and PI3K 
pathways. Our large scale screening of gynecologic cancers discovered frequent TERT 
promoter mutations in ovarian clear cell carcinoma. The findings generated from these 
works not only advance our understanding of the pathogenesis of uterine serous 
carcinoma and ovarian clear cell carcinoma, but also pave the way for future 






        Mutations identified in the discovery set† 
 




acid) Mutation Type Validation 
702TS ABCB4 NM_000443.3 g.chr7:86894096C>A c.1970G>T p.(Gly657Val) missense somatic 
555TS ABCC2 NM_000392.2 g.chr10:101557822C>T c.1669-8C>T p.? splice site no data 
702TS ABCD2 NM_005164.2 g.chr12:38297194T>C c.983A>G p.(Asp328Gly) missense no data 
993TCS ABCE1 NM_002940.2 g.chr4:146260738T>C c.1127T>C p.(Val376Ala) missense no data 
702TS ABHD12 NM_001042472.2 g.chr20:25245700C>A c.557G>T p.(Arg186Leu) missense no data 
DM851T ABHD3 NM_138340.3 g.chr18:17538460C>T c.162+3G>A p.? splice site no data 
863TCS ABI3BP NM_015429.3 g.chr3:102068424C>T c.998G>A p.(Arg333Gln) missense no data 
900T ACAD8 NM_014384.2 g.chr11:133634760C>T c.616C>T p.(Arg206*) nonsense no data 
FM474T ACTA1 NM_001100.3 g.chr1:227634516C>T c.656G>A p.(Cys219Tyr) missense somatic 
FM403T ADAD2 NM_139174.3 g.chr16:82787816C>T c.1835C>T p.(Ala612Val) missense somatic 
900T ADAM29 NM_001130703.1 g.chr4:176135307G>A c.2056G>A p.(Val686Ile) missense somatic 
DM851T ADAMTS12 NM_030955.2 g.chr5:33563151T>A c.4684A>T p.(Thr1562Ser) missense somatic 
555TS ADNP NM_015339.2 g.chr20:48944374T>C c.284A>G p.(Asn95Ser) missense no data 
702TS AGBL2 NM_024783.3 g.chr11:47670288T>C c.791A>G p.(Asn264Ser) missense no data 
702TS AIG1 NM_016108.2 g.chr6:143696215A>T c.619A>T p.(Met207Leu) missense no data 
863TCS AKAP9 NM_005751.3 g.chr7:91562389G>A c.9695G>A p.(Gly3232Glu) missense somatic 




20) frameshift somatic 
FM474T ALPK1 NM_025144.3 g.chr4:113572735G>A c.2583G>A p.(Met861Ile) missense somatic 
DM851T AMOTL2 NM_016201.2 g.chr3:135569123G>A c.947C>T p.(Ala316Val) missense somatic 
340TS AMPD2 NM_004037.6 g.chr1:109973565G>T c.1954G>T p.(Asp652Tyr) missense somatic 
FM474T ANAPC4 NM_013367.2 g.chr4:25000869G>A c.529G>A p.(Val177Ile) missense somatic 
900T ANK3 NM_020987.2 g.chr10:61501932G>A c.8713C>T p.(Arg2905Cys) missense somatic 
993TCS ANKFN1 NM_153228.2 g.chr17:51875250G>A c.1065G>A p.(Trp355*) nonsense no data 
FM403T ANLN NM_018685.2 g.chr7:36426850G>T c.2135G>T p.(Cys712Phe) missense no data 
900T APBB1 NM_001164.2 g.chr11:6380974G>A c.1081C>T p.(Arg361Trp) missense no data 
900T ARAP2 NM_015230.2 g.chr4:35825583T>A c.3181A>T p.(Arg1061*) nonsense no data 
702TS ARFIP2 NM_012402.2 g.chr11:6455522A>C c.870+2T>G p.? splice site somatic 
FM403T ARPC1B NM_005720.2 g.chr7:98826661G>C c.707+3G>C p.? splice site somatic 
DM851T ATAD5 NM_024857.3 g.chr17:26186100C>T c.875C>T p.(Pro292Leu) missense somatic 
FM403T ATN1 NM_001007026.1 g.chr12:6920322C>T c.3233C>T p.(Pro1078Leu) missense somatic 
900T ATP2A1 NM_004320.3 g.chr16:28806487G>A c.871G>A p.(Gly291Arg) missense somatic 
900T ATP6AP1L NM_001017971.1 g.chr5:81637056G>A c.80G>A p.(Trp27*) nonsense somatic 
FM403T ATR NM_001184.3 g.chr3:143760841G>C c.1674C>G p.(Asp558Glu) missense somatic 
900T ATXN2 NM_002973.2 g.chr12:110443069G>A c.1268C>T p.(Thr423Ile) missense no data 




FM474T BCL9 NM_004326.2 g.chr1:145558572C>T c.1987C>T p.(Pro663Ser) missense somatic 
863TCS BCOR NM_001123385.1 g.chrX:39818331C>A c.1212G>T p.(Gln404His) missense no data 
863TCS BRCA2 NM_000059.3 g.chr13:31811617G>T c.5125G>T p.(Asp1709Tyr) missense somatic 
993TCS BRPF1 NM_004634.2 g.chr3:9756161G>T c.1078G>T p.(Val360Phe) missense somatic 
366TS BSN NM_003458.3 g.chr3:49670367C>G c.8374C>G p.(Gln2792Glu) missense somatic 
863TCS BSN NM_003458.3 g.chr3:49664680G>A c.2687G>A p.(Arg896His) missense somatic 
993TCS C10orf131 NM_001130446.2 g.chr10:97677018dup c.250dup 
p.(Ser84Lysfs*1
0) frameshift somatic 
993TCS C12orf51 NM_001109662.2 g.chr12:111141659dup c.6473dup 
p.(Glu2159Glyfs
*5) frameshift somatic 
900T C15orf2 NM_018958.2 g.chr15:22475363G>A c.3256G>A p.(Ala1086Thr) missense no data 
FM474T C18orf19 NM_001098801.1 g.chr18:13672046G>A c.31C>T p.(Arg11*) nonsense no data 
366TS C19orf45 NM_198534.1 g.chr19:7476944T>C c.1058T>C p.(Phe353Ser) missense no data 
FM403T C21orf66 NM_016631.3 g.chr21:33045182C>G c.1640G>C p.(Gly547Ala) missense no data 
702TS C22orf43 NM_016449.3 g.chr22:22285482G>A c.679C>T p.(His227Tyr) missense no data 
FM403T C4orf49 NM_032623.3 g.chr4:140407397G>T c.529C>A p.(Pro177Thr) missense no data 
900T C5orf38 NM_178569.2 g.chr5:2806457C>A c.392C>A p.(Pro131Gln) missense no data 
DM851T C6orf138 NM_001013732.3 g.chr6:47954206G>A c.2333C>T p.(Ser778Leu) missense no data 
702TS C8orf48 NM_001007090.2 g.chr8:13469664C>G c.793C>G p.(Leu265Val) missense no data 
366TS CACHD1 NM_020925.2 g.chr1:64820479G>A c.161G>A p.(Arg54Gln) missense no data 
FM474T CACNA1A NM_001127222.1 g.chr19:13183920G>T c.6300C>A p.(Asn2100Lys) missense somatic 
702TS CACNA1B NM_000718.1 g.chr9:140087825G>A c.4739G>A p.(Arg1580His) missense somatic 
FM474T CACNA1F NM_005183.2 g.chrX:48948687G>A c.5788C>T p.(Arg1930Cys) missense somatic 
FM474T CAMSAP1 NM_015447.3 g.chr9:137852716del c.3612del 
p.(Ser1204Argfs
*2) frameshift somatic 
366TS CAND1 NM_018448.2 g.chr12:65985615C>G c.1900C>G p.(Leu634Val) missense somatic 
555TS CAP1 NM_006367.3 g.chr1:40309231G>A c.1337G>A p.(Gly446Asp) missense no data 
555TS CASR NM_000388.3 g.chr3:123485980G>A c.2489G>A p.(Gly830Asp) missense no data 
900T CATSPER3 NM_178019.1 g.chr5:134360063C>T c.454C>T p.(Arg152Cys) missense no data 
FM474T CCAR1 NM_018237.2 g.chr10:70172262T>G c.448T>G p.(Phe150Val) missense somatic 
900T CCBL1 NM_004059.4 g.chr9:130644881G>T c.74C>A p.(Ala25Asp) missense no data 
863TCS CCDC73 NM_001008391.2 g.chr11:32591585T>C c.2855A>G p.(Lys952Arg) missense no data 
FM474T CCDC88A NM_001135597.1 g.chr2:55414868C>T c.2593G>A p.(Glu865Lys) missense no data 
FM474T CDK9 NM_001261.3 g.chr9:129590061C>T c.280C>T p.(Arg94Cys) missense somatic 
900T CEP290 NM_025114.3 g.chr12:87001054G>T c.4897C>A p.(Gln1633Lys) missense somatic 
863TCS CHADL NM_138481.1 g.chr22:39963347C>G c.1675G>C p.(Glu559Gln) missense somatic 
900T CHD4 NM_001273.2 g.chr12:6567357C>T c.3485G>A p.(Arg1162Gln) missense somatic 
863TCS CHN2 NM_004067.2 g.chr7:29360793G>A c.77G>A p.(Trp26*) nonsense no data 
FM474T CHRNB4 NM_000750.3 g.chr15:76708405A>C c.1297T>G p.(Phe433Val) missense no data 




45) frameshift somatic 
FM474T CLK1 NM_001162407.1 g.chr2:201430948T>C c.784A>G p.(Ser262Gly) missense no data 
FM474T CLUL1 NM_014410.4 g.chr18:623407C>G c.966C>G p.(Cys322Trp) missense somatic 
993TCS CNGB3 NM_019098.4 g.chr8:87749503G>A c.503C>T p.(Thr168Met) missense somatic 
900T CNTNAP2 NM_014141.4 g.chr7:146448999C>T c.755-5C>T p.? splice site somatic 
FM403T COG5 NM_006348.2 g.chr7:106752162A>C c.1160T>G p.(Val387Gly) missense somatic 
863TCS COG7 NM_153603.3 g.chr16:23311237C>T c.2111G>A p.(Ser704Asn) missense somatic 




555TS COL19A1 NM_001858.4 g.chr6:70951308C>T c.2776-8C>T p.? splice site no data 
863TCS COL23A1 NM_173465.2 g.chr5:177605855G>A c.1413+6C>T p.? splice site no data 
DM851T CRISPLD1 NM_031461.5 g.chr8:76100392G>T c.1301G>T p.(Gly434Val) missense no data 
702TS CRNKL1 NM_016652.4 
g.chr20:19966059_19966
061del c.2290_2292del p.(Glu764del) in-frame indel no data 
555TS CSE1L NM_001316.2 g.chr20:47122567A>T c.992A>T p.(Lys331Met) missense no data 
340TS CTNND2 NM_001332.2 g.chr5:11071136C>T c.3034G>A p.(Val1012Ile) missense somatic 
555TS CYBB NM_000397.3 g.chrX:37537884A>G c.364A>G p.(Asn122Asp) missense no data 
FM474T CYBRD1 NM_024843.3 g.chr2:172119387C>T c.665C>T p.(Pro222Leu) missense somatic 
340TS CYP2D6 NM_000106.4 g.chr22:40855113T>C c.371A>G p.(Tyr124Cys) missense no data 
702TS DAZAP1 NM_170711.1 g.chr19:1383662C>G c.1210C>G p.(Gln341Glu) missense somatic 
993TCS DBC1 NM_014618.2 g.chr9:120969598C>T c.1871G>A p.(Arg624Gln) missense somatic 
900T DCST2 NM_144622.2 g.chr1:153268325G>T c.1342+8C>A p.? splice site no data 
366TS DECR2 NM_020664.3 g.chr16:400983G>A c.673G>A p.(Ala225Thr) missense no data 
FM403T DEF6 NM_022047.3 g.chr6:35373661C>T c.50C>T p.(Ala17Val) missense no data 
FM474T DEFA4 NM_001925.1 g.chr8:6781741C>T c.91G>A p.(Gly31Ser) missense no data 
702TS DEPDC5 NM_014662.2 g.chr22:30596648G>C c.3310G>C p.(Asp1104His) missense no data 
702TS DGKB NM_004080.1 g.chr7:14613621G>A c.1399C>T p.(Gln467*) nonsense no data 
702TS DGKI NM_004717.2 g.chr7:136732696G>T c.2948C>A p.(Pro983His) missense somatic 
FM403T DGKQ NM_001347.2 g.chr4:952591C>T c.451+8G>A p.? splice site somatic 
900T DHRS11 NM_024308.3 g.chr17:32028805G>A c.452+6G>A p.? splice site somatic 
FM403T DHX37 NM_032656.3 g.chr12:124016217G>A c.1685C>T p.(Ala562Val) missense somatic 
702TS DHX9 NM_001357.4 g.chr1:181079160G>C c.220G>C p.(Glu74Gln) missense no data 
555TS DIO2 NM_000793.4 g.chr14:79739389C>T c.223-5G>A p.? splice site no data 
FM403T DKKL1 NM_014419.3 g.chr19:54560885G>T c.348G>T p.(Glu116Asp) missense somatic 
900T DNAH11 NM_003777.3 g.chr7:21621329G>A c.3925G>A p.(Ala1309Thr) missense somatic 
FM403T DNAH11 NM_003777.3 g.chr7:21711649T>C c.6537T>C p.(Val2179Ala) missense no data 
900T DOCK9 NM_001130048.1 g.chr13:98281720C>G c.4449G>C p.(Lys1483Asn) missense no data 
FM474T DSCR3 NM_006052.1 g.chr21:37522393C>G c.658+1G>C p.? splice site no data 
900T E2F8 NM_024680.2 g.chr11:19212891G>T c.742C>A p.(Leu248Ile) missense no data 
FM403T EML1 NM_001008707.1 g.chr14:99456937G>C c.1936G>C p.(Glu646Gln) missense somatic 
702TS EPHA5 NM_004439.4 g.chr4:65899722C>A c.2488G>T p.(Glu830*) nonsense somatic 
863TCS ERAP1 NM_016442.3 g.chr5:96145526G>T c.1958C>A p.(Ser653Tyr) missense no data 
900T ERCC5 NM_000123.3 g.chr13:102316619T>G c.2206T>G p.(Leu736Val) missense somatic 
FM474T F5 NM_000130.4 g.chr1:167763840C>G c.5536G>C p.(Gly1846Arg) missense no data 
702TS F9 NM_000133.3 g.chrX:138471580G>A c.1070G>A p.(Gly357Glu) missense no data 
DM851T FAIM2 NM_012306.3 g.chr12:48569218A>T c.686T>A p.(Val229Glu) missense no data 




2) frameshift no data 
366TS FAM178A NM_018121.3 g.chr10:102666752A>T c.620A>T p.(Asp207Val) missense no data 
863TCS FAM196A NM_001039762.2 g.chr10:128864117T>G c.533A>C p.(Asn178Thr) missense no data 
702TS FAM38B NM_022068.2 g.chr18:10742821A>G c.3905T>C p.(Leu1302Pro) missense somatic 
863TCS FAM55A NM_152315.2 g.chr11:113903801C>T c.440G>A p.(Arg147His) missense somatic 
863TCS FAM65B NM_014722.2 g.chr6:24973582C>G c.490G>C p.(Ala164Pro) missense somatic 
993TCS FAM71B NM_130899.2 g.chr5:156522665G>T c.1189C>A p.(Pro397Thr) missense somatic 
366TS FBXW7 NM_033632.2 g.chr4:153468834C>T c.1394G>A p.(Arg465His) missense somatic 




DM851T FBXW7 NM_033632.2 g.chr4:153468834C>A c.1394G>T p.(Arg465Leu) missense somatic 
340TS FBXW8 NM_012174.1 g.chr12:115946462G>A c.1297G>A p.(Val433Met) missense somatic 
863TCS FER1L5 NM_001113382.1 g.chr2:96728258C>T c.4561C>T p.(Arg1521*) nonsense somatic 
702TS FILIP1L NM_182909.2 g.chr3:101052199T>G c.1011A>C p.(Leu337Phe) missense somatic 
340TS FMN2 NM_020066.3 g.chr1:238438656G>A c.4349+1G>A p.? splice site no data 
863TCS FNDC1 NM_032532.2 g.chr6:159573602G>A c.2068G>A p.(Gly690Ser) missense no data 
FM403T FRMD1 NM_024919.2 g.chr6:168210321G>A c.424C>T p.(Arg142*) nonsense somatic 
900T G6PD NM_000402.3 g.chrX:153413657G>C c.1487C>G p.(Thr496Ser) missense somatic 
993TCS GABRA1 NM_000806.4 g.chr5:161250560G>T c.782G>T p.(Cys261Phe) missense somatic 
702TS GCH1 NM_000161.2 g.chr14:54401881C>G c.367G>C p.(Asp123His) missense somatic 
DM851T GDAP1 NM_018972.2 g.chr8:75435064T>A c.448T>A p.(Ser150Thr) missense somatic 
FM403T GGCT NM_024051.2 g.chr7:30504977G>C c.390C>G p.(Tyr130*) nonsense somatic 
FM474T GIMAP1 NM_130759.3 g.chr7:150048809G>T c.784G>T p.(Ala262Ser) missense no data 
993TCS GPAA1 NM_003801.3 g.chr8:145212595T>C c.1583T>C p.(Met528Thr) missense no data 
DM851T GPC5 NM_004466.4 g.chr13:90899124C>T c.272C>T p.(Thr91Met) missense no data 
863TCS GPNMB NM_001005340.1 g.chr7:23266594T>A c.701-6T>A p.? splice site no data 
863TCS GPR101 NM_054021.1 g.chrX:135940171G>T c.1329C>A p.(Phe443Leu) missense no data 
900T GPR115 NM_153838.3 g.chr6:47790123T>G c.1183T>G p.(Ser395Ala) missense no data 
FM474T GPR32 NM_001506.1 g.chr19:55966712G>A c.1043G>A p.(Cys348Tyr) missense no data 
FM474T GPRASP2 NM_001004051.3 g.chrX:101858496A>C c.2043A>C p.(Gln681His) missense no data 
FM403T GRB10 NM_001001555.1 g.chr7:50704957G>A c.286C>T p.(Leu96Phe) missense no data 
555TS GRIN3A NM_133445.2 g.chr9:103472603G>C c.1912C>G p.(Arg638Gly) missense no data 
702TS GRLF1 NM_004491.4 g.chr19:52184763G>T c.4027G>T p.(Glu1343*) nonsense no data 
993TCS GRM5 NM_000842.3 g.chr11:88420093G>T c.596C>A p.(Ala199Glu) missense no data 
863TCS GTPBP3 NM_133644.3 g.chr19:17311393G>A c.1055G>A p.(Arg352Gln) missense no data 
FM403T HEBP2 NM_014320.2 g.chr6:138768909A>G c.347A>G p.(Gln116Arg) missense somatic 
863TCS HFM1 NM_001017975.3 g.chr1:91591213C>T c.1814G>A p.(Gly605Glu) missense no data 
993TCS HHLA1 NM_001145095.1 g.chr8:133161359G>A c.713C>T p.(Pro238Leu) missense no data 




5) frameshift no data 
FM474T HIST1H2BN NM_003520.3 g.chr6:27914794A>C c.376A>C p.(Lys126Gln) missense somatic 
FM474T HNRNPL NM_001533.2 g.chr19:44019268G>A c.1712-8C>T p.? splice site no data 
702TS HNRNPM NM_005968.3 g.chr19:8434397C>G c.344+9C>G p.? splice site no data 
702TS HRG NM_000412.2 g.chr3:187870414C>G c.301-7C>G p.? splice site no data 
555TS HS3ST4 NM_006040.2 g.chr16:26054688C>A c.989C>A p.(Ala330Asp) missense no data 
702TS HSF4 NM_001040667.2 g.chr16:65761139G>A c.1429G>A p.(Glu477Lys) missense no data 
702TS HSPG2 NM_005529.5 g.chr1:22087146A>T c.575T>A p.(Val192Glu) missense no data 
DM851T HUWE1 NM_031407.4 g.chrX:53595086G>T c.8962C>A p.(Gln2988Lys) missense somatic 
DM851T HUWE1 NM_031407.4 g.chrX:53674666G>T c.808C>A p.(His270Asn) missense somatic 
DM851T HYAL1 NM_153281.1 g.chr3:50313509C>T c.904G>A p.(Glu302Lys) missense somatic 
FM403T IBTK NM_015525.2 g.chr6:82977992C>T c.2308G>A p.(Val770Met) missense somatic 
FM403T IGSF21 NM_032880.4 g.chr1:18561222G>A c.451G>A p.(Ala151Thr) missense somatic 
366TS IL1RAPL1 NM_014271.3 g.chrX:29883626G>A c.1859G>A p.(Arg620His) missense somatic 
FM403T IL1RL2 NM_003854.2 g.chr2:102170745C>G c.-12-3C>G p.? splice site no data 
555TS INTS2 NM_020748.2 g.chr17:57357226C>T c.334G>A p.(Gly112Ser) missense no data 
900T ISCA1 NM_030940.3 g.chr9:88078982A>G c.82-5T>C p.? splice site no data 




900T KALRN NM_001024660.2 g.chr3:125868613G>A c.6593G>A p.(Arg2198Lys) missense somatic 
702TS KCNN2 NM_021614.2 
g.chr5:g.113726542_113
726544dup c.171_173dup p.(Ala58dup) in-frame indel no data 
FM403T KCNV2 NM_133497.3 g.chr9:2708796G>A c.1057G>A p.(Glu353Lys) missense no data 




22) frameshift no data 
863TCS KCTD15 NM_001129995.1 g.chr19:38989615C>T c.250C>T p.(Arg84Cys) missense somatic 
863TCS KCTD8 NM_198353.2 g.chr4:43871622dup c.1368dup 
p.(Pro457Serfs*1
0) frameshift somatic 
702TS KIAA0564 NM_015058.1 g.chr13:41047887C>T c.5359G>A p.(Glu1787Lys) missense no data 
FM403T KIAA0802 NM_015210.3 g.chr18:8783089A>G c.1981A>G p.(Thr661Ala) missense somatic 
FM403T KIAA1009 NM_014895.2 g.chr6:84919053T>C c.3559A>G p.(Ile1187Val) missense no data 
FM474T KIAA1370 NM_019600.2 g.chr15:50666718A>G c.2809-10T>C p.? splice site no data 
FM403T KIAA1731 NM_033395.1 g.chr11:93095966G>A c.6059G>A p.(Arg2020Gln) missense no data 
993TCS KIAA2022 NM_001008537.2 g.chrX:73877839C>G c.3278G>C p.(Gly1093Ala) missense somatic 
FM403T KIF20B NM_016195.2 g.chr10:91504408A>T c.4381A>T p.(Met1461Leu) missense somatic 
FM403T KLHDC8A NM_018203.1 g.chr1:203579235C>G c.121G>C p.(Asp41His) missense no data 
FM474T KLHL15 NM_030624.2 g.chrX:23916963T>A c.811A>T p.(Lys271*) nonsense no data 
FM474T KLK8 NM_007196.2 g.chr19:56192946A>T c.500T>A p.(Phe167Tyr) missense no data 
863TCS KRAS NM_033360.2 g.chr12:25289548C>T c.38G>A p.(Gly13Asp) missense somatic 
702TS KRT76 NM_015848.4 g.chr12:51452839C>T c.967G>A p.(Glu323Lys) missense no data 




p p.(Ala424dup) in-frame indel somatic 
DM851T LAMA5 NM_005560.3 g.chr20:60361618del c.536del 
p.(Gly179Alafs*
57) frameshift somatic 
FM474T LDB3 NM_007078.2 g.chr10:88431381C>T c.530C>T p.(Ala177Val) missense somatic 
702TS LEO1 NM_138792.2 g.chr15:50038281C>T c.1195G>A p.(Glu399Lys) missense no data 
FM474T LEPREL1 NM_018192.3 g.chr3:191187313T>C c.1146A>G p.(Ile382Met) missense somatic 
FM474T LGALS12 NM_001142535.1 g.chr11:63032987G>T c.389G>T p.(Arg130Leu) missense somatic 
555TS LHFP NM_005780.2 g.chr13:38850603C>T c.446G>A p.(Arg149Gln) missense no data 
993TCS LOC643677 NM_001146197.1 g.chr13:102183533G>A c.17515C>T p.(Arg5839Trp) missense no data 
900T LOC645961 NM_001166137.1 g.chr9:89937258C>T c.514G>A p.(Ala172Thr) missense no data 
FM474T LRCH3 NM_032773.2 g.chr3:199043592A>G c.1102+7A>G p.? splice site somatic 
702TS LRIT2 NM_001017924.2 g.chr10:85972257T>G c.1052A>C p.(His351Pro) missense no data 
555TS LSM14A NM_015578.2 g.chr19:39398414C>A c.781+8C>A p.? splice site no data 
FM474T MADD NM_003682.2 g.chr11:47263100G>T c.2190G>T p.(Lys730Asn) missense somatic 
702TS MAGEE2 NM_138703.4 g.chrX:74921009G>T c.603C>A p.(Asp201Glu) missense somatic 
900T MAGEL2 NM_019066.3 g.chr15:21440792C>T c.1382G>A p.(Arg461His) missense somatic 
555TS MAPK10 NM_138982.1 g.chr4:87171559A>G c.1160T>C p.(Ile387Thr) missense no data 
FM403T MAPRE3 NM_012326.2 g.chr2:27100631A>C c.431A>C p.(Gln144Pro) missense somatic 
863TCS MATN2 NM_002380.3 g.chr8:99023288C>G c.820C>G p.(Gln274Glu) missense somatic 
FM403T MBOAT4 NM_001100916.1 g.chr8:30109022C>A c.1287G>T p.(Lys429Asn) missense somatic 
993TCS MCAT NM_173467.4 g.chr22:41859424G>C c.742C>G p.(Leu248Val) missense somatic 
DM851T MESDC1 NM_022566.2 g.chr15:79082484C>T c.817C>T p.(Arg273Cys) missense no data 
702TS MGAM NM_004668.1 g.chr7:141373951T>A c.1168T>A p.(Leu390Ile) missense no data 
702TS MKS1 NM_017777.3 g.chr17:53645404C>T c.796G>A p.(Asp266Asn) missense no data 
702TS MLL3 NM_170606.2 g.chr7:151466914T>C c.14543A>G p.(Asn4848Ser) missense somatic 
DM851T MRGPRX4 NM_054032.3 g.chr11:18151635C>T c.256C>T p.(Arg86Cys) missense no data 




863TCS MTHFSD NM_001159378.1 g.chr16:85145861G>T c.17-3C>A p.? splice site no data 
FM474T MTUS2 NM_001033602.2 g.chr13:28498054G>T c.1249G>T p.(Asp417Tyr) missense somatic 
702TS MYCBPAP NM_032133.3 g.chr17:45955426C>T c.1403C>T p.(Pro468Leu) missense somatic 
702TS MYH1 NM_005963.3 g.chr17:10340126C>T c.5035G>A p.(Glu1679Lys) missense somatic 
340TS MYH11 NM_001040113.1 g.chr16:15722276G>A c.4733C>T p.(Ala1578Val) missense somatic 
FM474T MYH7 NM_000257.2 g.chr14:22954093A>G c.5510T>C p.(Val1837Ala) missense somatic 
FM474T MYH7 NM_000257.2 g.chr14:22954094C>A c.5509G>T p.(Val1837Leu) missense somatic 
FM474T MYO16 NM_015011.1 g.chr13:108177882C>G c.391C>G p.(His131Asp) missense no data 
FM474T MYO18B NM_032608.5 g.chr22:24554897C>T c.2941C>T p.(Gln981*) nonsense somatic 
DM851T NADK NM_023018.4 g.chr1:1674334G>A c.1210C>T p.(Pro404Ser) missense somatic 
FM403T NBEAL1 NM_001114132.1 
g.chr2:203705036_20370
5038del c.3574_3576del p.(Leu1192del) in-frame indel no data 
863TCS NBPF3 NM_032264.2 g.chr1:21678443C>G c.1171C>G p.(Gln391Glu) missense no data 
FM403T NCOA2 NM_006540.2 g.chr8:71231846C>T c.1308G>A p.(Met436Ile) missense somatic 
863TCS NCOA3 NM_006534.3 g.chr20:45696353A>T c.1112+7A>T p.? splice site somatic 
555TS NDOR1 NM_001144026.1 g.chr9:139229707G>A c.1201G>A p.(Val401Met) missense no data 
863TCS NEB NM_001164508.1 g.chr2:152112226A>G c.20330T>C p.(Val6777Ala) missense somatic 
FM403T NEB NM_001164508.1 g.chr2:152071734T>A c.23491A>T p.(Ile7831Phe) missense somatic 
702TS NEDD4 NM_198400.2 g.chr15:53995781A>G c.541T>C p.(Tyr181His) missense somatic 
900T NFATC1 NM_006162.3 g.chr18:75272172C>A c.909C>A p.(Asn303Lys) missense no data 
702TS NFXL1 NM_152995.4 g.chr4:47571924G>C c.2223C>G p.(Ile741Met) missense somatic 
FM474T NGEF NM_019850.2 g.chr2:233452546C>T c.2030G>A p.(Arg677Gln) missense somatic 




2) frameshift somatic 
FM474T NKAIN4 NM_152864.3 g.chr20:61351745C>T c.179G>A p.(Arg60His) missense somatic 




9) frameshift somatic 
DM851T NLRP13 NM_176810.2 g.chr19:61101967G>A c.2963C>T p.(Ala988Val) missense no data 
FM403T NMD3 NM_015938.3 g.chr3:162449969dup c.1236dup 
p.(Arg413Thrfs*
5) frameshift somatic 
702TS NOLC1 NM_004741.3 
g.chr10:103907043_1039
07045del c.285_287del p.(Glu96del) in-frame indel no data 
FM474T NOTCH3 NM_000435.2 g.chr19:15152049A>C c.3161T>G p.(Leu1054Arg) missense no data 
863TCS NSD1 NM_022455.3 g.chr5:176653628T>C c.6653T>C p.(Ile2218Thr) missense no data 
900T NSUN2 NM_017755.4 g.chr5:6675214C>T c.538-1G>A p.? splice site no data 
863TCS NTSR1 NM_002531.2 g.chr20:60811420C>T c.416C>T p.(Ala139Val) missense no data 
863TCS NUAK1 NM_014840.2 g.chr12:104984900C>T c.1796G>A p.(Arg599His) missense no data 
863TCS NUP205 NM_015135.2 g.chr7:134926735C>T c.1474-3C>T p.? splice site no data 
FM474T NUP54 NM_017426.2 g.chr4:77276523G>A c.362C>T p.(Ala121Val) missense no data 
FM474T NXT2 NM_018698.4 g.chrX:108666846G>C c.120G>C p.(Glu40Asp) missense no data 
555TS OBSCN NM_001098623.1 g.chr1:226631126A>T c.22967A>T p.(Glu7656Val) missense no data 






*10) frameshift somatic 
FM403T ODZ2 NM_001122679.1 g.chr5:167457629C>T c.1732C>T p.(Arg578Cys) missense somatic 
702TS OR1E1 NM_003553.2 g.chr17:3248271A>T c.184T>A p.(Phe62Ile) missense somatic 
993TCS OR2L13 NM_175911.2 g.chr1:246329935G>A c.635G>A p.(Gly212Asp) missense somatic 
DM851T OR4L1 NM_001004717.1 g.chr14:19598968G>T c.925G>T p.(Ala309Ser) missense somatic 
FM403T OR5H14 NM_001005514.1 g.chr3:99351050G>A c.131G>A p.(Gly44Asp) missense no data 
555TS OR5P2 NM_153444.1 g.chr11:7774393G>A c.673C>T p.(Arg225Cys) missense no data 




FM474T OR7D2 NM_175883.1 g.chr19:9158328A>G c.871A>G p.(Ser291Gly) missense no data 
DM851T ORAI2 NM_001126340.1 g.chr7:101866622G>A c.214G>A p.(Gly72Ser) missense somatic 
FM474T ORAI2 NM_001126340.1 g.chr7:101874136T>G c.397T>G p.(Ser133Ala) missense somatic 
702TS ORC1L NM_004153.3 g.chr1:52611557A>T c.2470T>A p.(Ser824Thr) missense somatic 
863TCS OSBPL5 NM_020896.2 g.chr11:3082059T>C c.1184A>G p.(Glu395Gly) missense somatic 
863TCS PA2G4 NM_006191.2 g.chr12:54791061G>A c.889G>A p.(Ala297Thr) missense somatic 
702TS PAH NM_000277.1 g.chr12:101770846A>C c.719T>G p.(Phe240Cys) missense somatic 
FM474T PAPPA NM_002581.3 g.chr9:118073475G>T c.2912G>T p.(Cys971Phe) missense somatic 
900T PAPPA2 NM_020318.2 g.chr1:174831226G>A c.1863G>A p.(Trp621*) nonsense somatic 
900T PARP15 NM_001113523.1 g.chr3:123812025G>A c.307-6G>A p.? splice site no data 
366TS PCDH15 NM_001142772.1 g.chr10:55452828C>G c.2356G>C p.(Glu786Gln) missense somatic 
FM474T PCDHA12 NM_018903.2 g.chr5:140237277C>T c.2036C>T p.(Ser679Leu) missense somatic 
702TS PCDHA6 NM_018909.2 g.chr5:140189776A>G c.1916A>G p.(Glu639Gly) missense no data 
702TS PCDHB12 NM_018932.3 g.chr5:140570717C>T c.2054C>T p.(Ser685Leu) missense somatic 
702TS PCDHGA7 NM_018920.2 g.chr5:140745036G>T c.2386G>T p.(Asp796Tyr) missense no data 
FM403T PCNXL2 NM_014801.3 g.chr1:231227628C>G c.4492G>C p.(Glu1498Gln) missense no data 
FM403T PCSK2 NM_002594.3 g.chr20:17410611C>G c.1813C>G p.(Arg605Gly) missense somatic 
FM474T PDCD6IP NM_013374.4 g.chr3:33861996A>T c.1553A>T p.(Asp518Val) missense somatic 
702TS PDE1A NM_005019.3 g.chr2:182761989C>A c.1217G>T p.(Cys406Phe) missense somatic 
993TCS PDGFRA NM_006206.4 g.chr4:54849968C>T c.2810C>T p.(Pro937Leu) missense somatic 
702TS PDS5A NM_015200.2 g.chr4:39586517T>G c.1006A>C p.(Ile336Leu) missense somatic 
702TS PDS5A NM_015200.2 g.chr4:39595064T>C c.755A>G p.(Lys252Arg) missense no data 
DM851T PHF16 NM_001077445.1 g.chrX:46730049C>G c.47-9C>G p.? splice site no data 
FM474T PHF3 NM_015153.2 g.chr6:64479500C>T c.4057C>T p.(Arg1353*) nonsense no data 
FM474T PHF3 NM_015153.2 g.chr6:64479503C>T c.4060C>T p.(Gln1354*) nonsense no data 
FM474T PI16 NM_153370.2 
g.chr6:37039604_370396
06del c.1299_1301del p.(Val434del) in-frame indel no data 
900T PIK3C2B NM_002646.2 g.chr1:202661477C>T c.4603G>A p.(Gly1535Arg) missense somatic 
702TS PIK3CA NM_006218.2 g.chr3:180410668G>A c.1252G>A p.(Glu418Lys) missense somatic 
863TCS PIK3CA NM_006218.2 g.chr3:180400172G>A c.353G>A p.(Gly118Asp) missense somatic 
FM403T PIK3CA NM_006218.2 g.chr3:180405018G>A c.1093G>A p.(Glu365Lys) missense somatic 
FM474T PIK3CA NM_006218.2 g.chr3:180404243T>G c.1031T>G p.(Val344Gly) missense somatic 
702TS PIK3R4 NM_014602.2 g.chr3:131883108C>T c.3625G>A p.(Glu1209Lys) missense somatic 
366TS PKD2L2 NM_014386.2 g.chr5:137269945G>C c.898G>C p.(Glu300Gln) missense somatic 
702TS PKHD1 NM_138694.3 g.chr6:51591933A>C c.12130T>G p.(Leu4044Val) missense somatic 
FM403T PLCH1 NM_014996.1 g.chr3:156682064C>G c.4355G>C p.(Cys1452Ser) missense no data 
FM403T PLD5 NM_152666.1 g.chr1:240337705C>G c.854G>C p.(Arg285Thr) missense no data 
FM474T PLEKHG7 NM_001004330.2 g.chr12:91672033G>T c.352G>T p.(Val118Leu) missense no data 
366TS PLG NM_000301.1 g.chr6:161072146G>A c.1330G>A p.(Val444Ile) missense no data 
702TS PLK4 NM_014264.4 g.chr4:129030572G>A c.1561G>A p.(Asp521Asn) missense no data 
863TCS PLLP NM_015993.2 g.chr16:55853490G>T c.136-7C>A p.? splice site no data 
FM474T POLR2E NM_002695.3 g.chr19:1045037A>G c.98T>C p.(Leu33Pro) missense somatic 
993TCS POP1 NM_015029.1 g.chr8:99237447T>C c.2058-7T>C p.? splice site no data 
555TS PPP2R1A NM_014225.3 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense somatic 
702TS PPP2R1A NM_014225.3 g.chr19:57408135C>A c.767C>A p.(Ser256Tyr) missense no data 
900T PRKACB NM_002731.2 g.chr1:84417471A>G c.70A>G p.(Lys24Glu) missense somatic 




FM403T PRR14 NM_024031.2 g.chr16:30573107C>A c.604C>A p.(Pro202Thr) missense no data 
DM851T PTCHD2 NM_020780.1 g.chr1:11484387C>T c.751C>T p.(Arg251*) nonsense somatic 
FM403T PTGIR NM_000960.3 g.chr19:51818632C>T c.691G>A p.(Gly231Arg) missense no data 
366TS PTGS1 NM_000962.2 g.chr9:124194279C>T c.1445-10C>T p.? splice site no data 
900T PTPLA NM_014241.3 g.chr10:17685566G>T c.482C>A p.(Pro161Gln) missense somatic 
FM403T PTPN7 NM_080588.1 g.chr1:200395159G>A c.112C>T p.(Leu38Phe) missense somatic 
FM403T PUS7 NM_019042.3 g.chr7:104919230C>G c.913G>C p.(Val305Leu) missense no data 
FM403T PWP1 NM_007062.1 g.chr12:106626872C>T c.1117C>T p.(Arg373Cys) missense no data 
863TCS RALGAPA2 NM_020343.3 g.chr20:20533849C>A c.2008G>T p.(Glu670*) nonsense no data 
900T RALGPS2 NM_152663.2 g.chr1:177127980T>C c.1248-8T>C p.? splice site no data 
FM474T RASA1 NM_002890.2 g.chr5:86709990G>A c.2366G>A p.(Arg789Gln) missense no data 
FM403T RASGEF1B NM_152545.1 g.chr4:82585758C>A c.874G>T p.(Val292Leu) missense no data 
900T RELN NM_005045.2 g.chr7:103109828C>T c.1260G>A p.(Trp420*) nonsense somatic 
FM403T RHBDL3 NM_138328.2 g.chr17:27672162G>T c.1016G>T p.(Ser339Ile) missense no data 
702TS RNF19B NM_153341.2 g.chr1:33186559G>C c.842-5C>G p.? splice site somatic 
FM403T RNF19B NM_153341.2 g.chr1:33183702C>A c.1264G>T p.(Gly422Cys) missense somatic 
863TCS RNF220 NM_018150.2 g.chr1:44650448C>T c.92C>T p.(Thr31Met) missense no data 
555TS RNF40 NM_014771.2 g.chr16:30685588del c.1319del 
p.(Lys440Serfs*
47) frameshift no data 
FM474T ROBO1 NM_133631.3 g.chr3:78767696T>G c.3155A>C p.(Lys1052Thr) missense somatic 
FM403T RPRD1A NM_018170.3 g.chr18:31867688C>T c.262G>A p.(Ala88Thr) missense somatic 
DM851T RYR2 NM_001035.2 g.chr1:235726459G>A c.1987G>A p.(Val663Ile) missense no data 
863TCS RYR3 NM_001036.3 g.chr15:31937393G>A c.14128G>A p.(Asp4710Asn) missense somatic 
366TS SCAMP3 NM_052837.2 g.chr1:153495231C>T c.439+10G>A p.? splice site no data 
993TCS SCN7A NM_002976.2 g.chr2:167037086C>T c.559G>A p.(Val187Ile) missense no data 
DM851T SDK2 NM_001144952.1 g.chr17:68873039dup c.5260dup 
p.(Leu1754Profs
*144) frameshift somatic 
DM851T SDR16C6 NM_001145251.1 g.chr8:57470436G>T c.43C>A p.(Pro15Thr) missense somatic 
900T SEC23B NM_006363.4 g.chr20:18444339G>A c.325G>A p.(Glu109Lys) missense somatic 
555TS SEC24D NM_014822.2 g.chr4:119869258G>A c.2869-5C>T p.? splice site no data 
366TS SEMA3E NM_012431.2 g.chr7:82957527C>A c.116-1G>T p.? splice site no data 
863TCS SENP7 NM_001077203.1 g.chr3:102702663C>A c.41-10G>T p.? splice site no data 
555TS SEPW1 NM_003009.2 g.chr19:52976167C>G c.109-10C>G p.? splice site no data 
702TS SERPINB10 NM_005024.1 g.chr18:59751313T>C c.685T>C p.(Phe229Leu) missense no data 
863TCS SF1 NM_004630.2 g.chr11:64293596C>T c.541G>A p.(Gly181Arg) missense no data 
863TCS SF3A1 NM_005877.4 g.chr22:29070958dup c.617dup 
p.(Asn206Lysfs*
29) frameshift no data 
DM851T SFMBT2 NM_001029880.1 g.chr10:7270679G>A c.1721C>T p.(Ala574Val) missense no data 
863TCS SGSM3 NM_015705.4 g.chr22:39131149G>A c.533G>A p.(Ser178Asn) missense no data 




5) frameshift somatic 
900T SHC1 NM_001130040.1 g.chr1:153205295G>A c.1219C>T p.(Arg407Cys) missense somatic 
DM851T SIGLEC7 NM_014385.2 g.chr19:56337865G>T c.427G>T p.(Val143Leu) missense no data 
702TS SLC26A9 NM_052934.2 g.chr1:204157406C>T c.1966G>A p.(Val656Ile) missense somatic 
FM403T SLC28A1 NM_004213.3 g.chr15:83288891G>A c.1754G>A p.(Cys585Tyr) missense somatic 
863TCS SLC2A3 NM_006931.1 g.chr12:7969742C>T c.931G>A p.(Ala311Thr) missense somatic 
900T SLC34A2 NM_006424.2 
g.chr4:25287260_252872
62del c.1864_1866del p.(Cys622del) in-frame indel no data 




FM474T SLC37A3 NM_032295.2 g.chr7:139698328C>A c.703+3G>T p.? splice site no data 
FM474T SLC37A3 NM_207113.1 g.chr7:139698329A>C c.703+2T>G p.? splice site no data 
FM474T SLC38A4 NM_018018.3 g.chr12:45459918A>C c.576-6T>G p.? splice site no data 
DM851T SLC39A7 NM_006979.2 g.chr6:33277608A>G c.520A>G p.(Ser174Gly) missense no data 
863TCS SLC47A2 NM_152908.3 g.chr17:19556619G>T c.475C>A p.(Pro159Thr) missense no data 
555TS SLC4A1AP NM_018158.2 g.chr2:27758720G>T c.1865G>T p.(Gly622Val) missense no data 
FM474T SLC4A4 NM_001098484.1 g.chr4:72648475G>A c.3196+5G>A p.? splice site no data 
DM851T SLC8A3 NM_183002.1 g.chr14:69704096C>T c.797G>A p.(Arg266His) missense no data 
702TS SLC9A9 NM_173653.1 g.chr3:145049708C>A c.147G>T p.(Leu49Phe) missense no data 
900T SLITRK2 NM_001144003.2 g.chrX:144713965G>T c.2330G>T p.(Cys777Phe) missense no data 
863TCS SLITRK3 NM_014926.2 g.chr3:166389136G>C c.2177C>G p.(Thr726Ser) missense no data 
555TS SMAD9 NM_001127217.2 g.chr13:36320869C>G c.1348G>C p.(Asp450His) missense no data 
DM851T SMPD4 NM_017951.4 g.chr2:130627966C>A c.1789G>T p.(Ala597Ser) missense somatic 
FM474T SNAP25 NM_130811.2 g.chr20:10221821G>A c.176G>A p.(Arg59His) missense no data 
702TS SNIP NM_025248.2 g.chr17:33970089C>T c.1793+6G>A p.? splice site no data 
900T SNRK NM_017719.4 g.chr3:43364425A>G c.1670A>G p.(Asp557Gly) missense no data 
366TS SPAG5 NM_006461.3 g.chr17:23936552C>T c.1865G>A p.(Gly622Glu) missense no data 
FM403T SPOP NM_003563.3 g.chr17:45051724C>T c.223G>A p.(Gly75Arg) missense somatic 
DM851T SPRYD3 NM_032840.2 g.chr12:51746648G>A c.997C>T p.(Arg333Trp) missense somatic 
900T SPTA1 NM_003126.2 g.chr1:156917066del c.610del 
p.(Gln204Lysfs*
5) frameshift somatic 
DM851T SPTA1 NM_003126.2 g.chr1:156884940C>T c.3697G>A p.(Val1233Ile) missense somatic 
993TCS SPTBN5 NM_016642.2 g.chr15:39950013G>A c.5485C>T p.(Arg1794*) nonsense somatic 
DM851T SSB NM_003142.3 g.chr2:170375043C>T c.674C>T p.(Ser225Phe) missense no data 
900T SSX2IP NM_001166417.1 g.chr1:84900639C>T c.757G>A p.(Asp253Asn) missense no data 
702TS ST8SIA3 NM_015879.2 g.chr18:53172714C>G c.263C>G p.(Ser88Cys) missense no data 
DM851T STAG3L4 NM_022906.2 g.chr7:66411555del c.286del 
p.(Leu96Trpfs*4
) frameshift no data 
863TCS STRN4 NM_013403.2 g.chr19:51922563C>T c.1234G>A p.(Asp412Asn) missense somatic 
340TS SUPT5H NM_001130824.1 g.chr19:44655971G>A c.2462G>A p.(Trp821*) nonsense somatic 
993TCS SVIL NM_021738.2 g.chr10:29879649G>A c.710C>T p.(Ser237Phe) missense somatic 
863TCS SYNE1 NM_182961.3 g.chr6:152594314C>T c.20944G>A p.(Val6982Met) missense somatic 
DM851T SYNE2 NM_182914.2 g.chr14:63546528G>A c.4669G>A p.(Val1557Ile) missense somatic 
FM474T TACR3 NM_001059.2 g.chr4:104798867T>A c.691A>T p.(Thr231Ser) missense somatic 
993TCS TAF1L NM_153809.2 g.chr9:32621851G>A c.3727C>T p.(Arg1243Trp) missense somatic 
FM403T TARBP1 NM_005646.3 g.chr1:232669901C>G c.1218G>C p.(Lys406Asn) missense no data 
FM403T TAS2R16 NM_016945.2 g.chr7:122422234C>T c.691G>A p.(Val231Ile) missense no data 
FM403T TBX6 NM_004608.2 g.chr16:30007814G>A c.572C>T p.(Ser191Phe) missense somatic 
340TS TIMM44 NM_006351.3 g.chr19:7909083C>A c.142-1G>T p.? splice site no data 
FM474T TKTL1 NM_012253.3 g.chrX:153190927G>A c.289G>A p.(Gly97Arg) missense somatic 
FM403T TKTL2 NM_032136.4 g.chr4:164613159A>G c.1178T>C p.(Phe393Ser) missense somatic 
702TS TLE4 NM_007005.3 g.chr9:81527185G>C c.1987-1G>C p.? splice site somatic 
900T TLR8 NM_138636.3 g.chrX:12847265G>A c.185G>A p.(Gly62Asp) missense somatic 
DM851T TMEM2 NM_013390.2 g.chr9:73535525G>C c.1689C>G p.(Tyr563*) nonsense no data 
702TS TMEM22 NM_025246.2 g.chr3:138056122G>C c.130G>C p.(Gly44Arg) missense no data 
FM403T TMPO NM_003276.2 g.chr12:97452066G>C c.1900G>C p.(Asp634His) missense no data 




340TS TP53 NM_000546.4 g.chr17:7519174C>T c.481G>A p.(Ala161Thr) missense somatic 
555TS TP53 NM_000546.4 g.chr17:7518276C>G c.730G>C p.(Gly244Arg) missense no data 
702TS TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense somatic 
863TCS TP53 NM_000546.4 g.chr17:7518284G>A c.722C>T p.(Ser241Phe) missense no data 
900T TP53 NM_000546.4 g.chr17:7518330del c.677del 
p.(Gly226Alafs*
21) frameshift somatic 
993TCS TP53 NM_000546.4 g.chr17:7517831G>T c.832C>A p.(Pro278Thr) missense somatic 
DM851T TP53 NM_000546.4 g.chr17:7518293C>T c.713G>A p.(Cys238Tyr) missense somatic 
FM403T TP53 NM_000546.4 
g.chr17:7518899_751892
7del c.647_672+3del p.(Val216Glyfs) frameshift no data 
FM474T TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense no data 
993TCS TP53BP1 NM_005657.1 g.chr15:41571538G>T c.225C>A p.(Asp75Glu) missense somatic 
900T TRAF7 NM_032271.2 g.chr16:2166310G>A c.1922G>A p.(Arg641His) missense somatic 
702TS TRAM1L1 NM_152402.2 g.chr4:118225657G>T c.341C>A p.(Ala114Glu) missense no data 
FM474T TRERF1 NM_033502.2 g.chr6:42312013C>T c.2974G>A p.(Val992Ile) missense no data 
993TCS TRIM59 NM_173084.2 g.chr3:161639163T>G c.503A>C p.(Lys168Thr) missense no data 
FM474T TRIO NM_007118.2 g.chr5:14350224G>A c.1220G>A p.(Arg407His) missense no data 
702TS TRMT6 NM_015939.3 g.chr20:5872263C>T c.609G>A p.(Met203Ile) missense no data 
863TCS TRPS1 NM_014112.2 g.chr8:116668393A>G c.2700+10T>C p.? splice site no data 
702TS TTC28 NM_001145418.1 g.chr22:26719314G>A c.5437C>T p.(Arg1813Trp) missense no data 






s*16) frameshift somatic 
DM851T TUBB1 NM_030773.3 g.chr20:57028027A>C c.55A>C p.(Lys19Gln) missense somatic 
702TS UBA2 NM_005499.2 g.chr19:39616146T>C c.347T>C p.(Leu116Ser) missense somatic 
FM474T UBA2 NM_005499.2 g.chr19:39614604A>T c.223-2A>T p.? splice site somatic 
FM403T UBAP1 NM_016525.3 g.chr9:34239816A>T c.1123A>T p.(Met375Leu) missense no data 
FM474T UBQLNL NM_145053.4 g.chr11:5493415T>C c.833A>G p.(Asn278Ser) missense somatic 
702TS UGT1A8 NM_019075.2 g.chr2:234345771G>T c.1420G>T p.(Ala474Ser) missense somatic 
900T UGT2B4 NM_021139.2 g.chr4:70381153G>A c.1375C>T p.(Arg459*) nonsense somatic 
555TS UPP2 NM_001135098.1 g.chr2:158682678G>A c.607G>A p.(Gly203Ser) missense no data 
FM474T UQCRC2 NM_003366.2 g.chr16:21887515T>C c.670+8T>C p.? splice site somatic 
900T URB2 NM_014777.2 g.chr1:227839624G>T c.2641G>T p.(Asp881Tyr) missense somatic 
FM403T URG4 NM_001077664.1 g.chr7:43885364C>A c.94G>T p.(Glu32*) nonsense somatic 
863TCS USP36 NM_025090.3 g.chr17:74314718G>A c.2003C>T p.(Pro668Leu) missense somatic 
FM403T USP53 NM_019050.2 g.chr4:120400479C>T c.626C>T p.(Ala209Val) missense somatic 
863TCS USP6 NM_004505.2 g.chr17:5015596T>C c.3955-10T>C p.? splice site no data 
863TCS UTRN NM_007124.2 g.chr6:145144900G>A c.8782G>A p.(Val2928Ile) missense no data 
FM474T UTRN NM_007124.2 g.chr6:144877478G>A c.5074-1G>A p.? splice site no data 
FM474T WBP5 NM_016303.2 g.chrX:102499522A>G c.254A>G p.(Asn85Ser) missense somatic 
FM403T WDR7 NM_015285.2 g.chr18:52509508A>C c.781A>C p.(Thr261Pro) missense somatic 
FM474T WDR90 NM_145294.4 g.chr16:641035C>A c.599C>A p.(Pro200His) missense somatic 
863TCS XKR7 NM_001011718.1 g.chr20:30048458C>T c.1277C>T p.(Ala426Val) missense no data 
FM474T ZBTB7B NM_015872.2 g.chr1:153253875C>T c.115C>T p.(Arg39Trp) missense no data 
555TS ZCCHC6 NM_024617.3 g.chr9:88147844G>A c.1052C>T p.(Ser351Leu) missense no data 
FM474T ZFP1 NM_153688.2 g.chr16:73761273T>C c.764T>C p.(Leu255Pro) missense somatic 
FM474T ZMYND10 NM_015896.2 g.chr3:50354521A>C c.928T>G p.(Leu310Val) missense somatic 
993TCS ZNF280C NM_017666.4 g.chrX:129177612T>C c.1672A>G p.(Ser558Gly) missense no data 




FM403T ZNF513 NM_144631.5 g.chr2:27454236G>A c.1306C>T p.(Arg436Cys) missense somatic 
FM403T ZNF518A NM_014803.3 g.chr10:97907690C>A c.1621C>A p.(Leu541Ile) missense no data 
340TS ZNF770 NM_014106.3 g.chr15:33061556G>A c.1372C>T p.(Gln458*) nonsense somatic 
993TCS ZPBP NM_001159878.1 g.chr7:49993649T>G c.793A>C p.(Ile265Leu) missense somatic 
702TS ZYG11A NM_001004339.2 g.chr1:53116026C>T c.1627C>T p.(Leu543Phe) missense somatic 
*Coordinates refer to human reference genome hg18 release (NCBI 36.1, March 
2006) 





Profiles of somatic mutations in TP53, PIK3CA, FBXW7 and PPP2R1A genes 







900T TP53 NM_000546.4 g.chr17:7518330del c.677del p.(Gly226Alafs*21) frameshift discovery 
702TS TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense discovery 
863TCS TP53 NM_000546.4 g.chr17:7518284G>A c.722C>T p.(Ser241Phe) missense discovery 
340TS TP53 NM_000546.4 g.chr17:7519174C>T c.481G>A p.(Ala161Thr) missense discovery 
993TCS TP53 NM_000546.4 g.chr17:7517831G>T c.832C>A p.(Pro278Thr) missense discovery 
FM403T TP53 NM_000546.4 g.chr17:7518899_7518927del c.647_672+3del p.(Val216Glyfs) frameshift discovery 
DM851T TP53 NM_000546.4 g.chr17:7518293C>T c.713G>A p.(Cys238Tyr) missense discovery 
FM474T TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense discovery 
555TS TP53 NM_000546.4 g.chr17:7518276C>G c.730G>C p.(Gly244Arg) missense discovery 
1FFPE TP53 NM_000546.4 g.chr17:7517831G>C c.832C>G p.(Pro278Ala) missense validation 
2FFPE TP53 NM_000546.4 g.chr17:7520121_7520130del c.282_291del p.(Ser95Leufs*25) frameshift validation 
2FFPE TP53 NM_000546.4 g.chr17:7518982C>A c.592G>T p.(Glu198*) nonsense validation 
3FFPE TP53 NM_000546.4 g.chr17:7519120G>T c.535C>A p.(His179Asn) missense validation 
3FFPE TP53 NM_000546.4 g.chr17:7517864G>A c.799C>T p.(Arg267Trp) missense validation 
4FFPE TP53 NM_000546.4 g.chr17:7518281C>G c.725G>C p.(Cys242Ser) missense validation 
5FFPE TP53 NM_000546.4 g.chr17:7519168A>G c.487T>C p.(Tyr163His) missense validation 
5FFPE TP53 NM_000546.4 g.chr17:7519119T>G c.536A>C p.(His179Pro) missense validation 
6FFPE TP53 NM_000546.4 g.chr17:7518982C>A c.592G>T p.(Glu198*) nonsense validation 
7FFPE TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense validation 
8FFPE TP53 NM_000546.4 g.chr17:7518284G>C c.722C>G p.(Ser241Cys) missense validation 
9FFPE TP53 NM_000546.4 g.chr17:7519131C>T c.524G>A p.(Arg175His) missense validation 
14FFPE TP53 NM_000546.4 g.chr17:7517845C>T c.818G>A p.(Arg273His) missense validation 
15FFPE TP53 NM_000546.4 g.chr17:7518915T>C c.659A>G p.(Tyr220Cys) missense validation 
16FFPE TP53 NM_000546.4 g.chr17:7519263T>C c.392A>G p.(Asn131Ser) missense validation 
19FFPE TP53 NM_000546.4 g.chr17:7518264G>A c.742C>T p.(Arg248Trp) missense validation 
20FFPE TP53 NM_000546.4 g.chr17:7517839C>A c.824G>T p.(Cys275Phe) missense validation 
21FFPE TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T p.(Arg273Cys) missense validation 
22FFPE TP53 NM_000546.4 g.chr17:7518263C>T c.743G>A p.(Arg248Gln) missense validation 
22FFPE TP53 NM_000546.4 g.chr17:7517580G>A c.991C>T p.(Gln331*) nonsense validation 
23FFPE TP53 NM_000546.4 g.chr17:7519131C>T c.524G>A p.(Arg175His) missense validation 
24FFPE TP53 NM_000546.4 g.chr17:7519131C>T c.524G>A p.(Arg175His) missense validation 
25FFPE TP53 NM_000546.4 g.chr17:7517833C>T c.830G>A p.(Cys277Tyr) missense validation 
25FFPE TP53 NM_000546.4 g.chr17:7517748_7517757del c.906_915del p.(Ser303Glufs*39) frameshift validation 
28FFPE TP53 NM_000546.4 g.chr17:7518263C>T c.743G>A p.(Arg248Gln) missense validation 
29FFPE TP53 NM_000546.4 g.chr17:7518306A>G c.700T>C p.(Tyr234His) missense validation 
30FFPE TP53 NM_000546.4 g.chr17:7519131C>T c.524G>A p.(Arg175His) missense validation 
31FFPE TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T p.(Arg273Cys) missense validation 




32FFPE TP53 NM_000546.4 g.chr17:7518993A>G c.581T>C p.(Leu194Pro) missense validation 
2360T TP53 NM_000546.4 g.chr17:7518243T>A c.763A>T p.(Ile255Phe) missense validation 
2748T TP53 NM_000546.4 g.chr17:7517580del c.991del p.(Gln331Argfs*14) frameshift validation 
2771T TP53 NM_000546.4 g.chr17:7518933T>C c.641A>G p.(His214Arg) missense validation 
2910T TP53 NM_000546.4 g.chr17:7518996T>A c.578A>T p.(His193Leu) missense validation 
30020T TP53 NM_000546.4 g.chr17:7518273C>T c.733G>A p.(Gly245Ser) missense validation 
34347T TP53 NM_000546.4 g.chr17:7520093A>C c.319T>G p.(Tyr107Asp) missense validation 
34451T TP53 NM_000546.4 g.chr17:7518291T>C c.715A>G p.(Asn239Asp) missense validation 
3572T TP53 NM_000546.4 g.chr17:7517813T>G c.850A>C p.(Thr284Pro) missense validation 
3746T TP53 NM_000546.4 g.chr17:7514727C>G c.1025G>C p.(Arg342Pro) missense validation 
4040TCS TP53 NM_000546.4 g.chr17:7518990_7518992del c.582_584del p.(Ile195del) 
in-frame 
indel validation 
4059T TP53 NM_000546.4 g.chr17:7519131C>T c.659A>G p.(Tyr220Cys) missense validation 
4059T TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T  p.(Arg273Cys) missense validation 
4285T TP53 NM_000546.4 g.chr17:7518960T>C c.614A>G p.(Tyr205Cys) missense validation 
4435T TP53 NM_000546.4 g.chr17:7520269_7520288dup c.124_143dup p.(Asp48Glufs*3) frameshift validation 
460TS TP53 NM_000546.4 g.chr17:7520119_7520120del c.292_293del p.(Pro98Phefs*50) frameshift validation 
62073T TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T p.(Arg273Cys) missense validation 
62958 TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T p.(Arg273Cys) missense validation 
64646 TP53 NM_000546.4 g.chr17:7519131C>T c.524G>A p.(Arg175His) missense validation 
64646 TP53 NM_000546.4 g.chr17:7517747G>A c.916C>T p.(Arg306*) nonsense validation 
EM66 TP53 NM_000546.4 g.chr17:7518263C>T c.743G>A p.(Arg248Gln) missense validation 
JB1428T TP53 NM_000546.4 g.chr17:7518272C>A c.734G>T p.(Gly245Val) missense validation 
JB2285 TP53 NM_000546.4 g.chr17:7518943del c.631del p.(Thr211Leufs*36) frameshift validation 
JB2411T TP53 NM_000546.4 g.chr17:7518289G>T c.717C>A p.(Asn239Lys) missense validation 
JB2582T TP53 NM_000546.4 g.chr17:7518249del c.757del p.(Thr253Profs*92) frameshift validation 
JB2653T TP53 NM_000546.4 g.chr17:7517846G>A c.817C>T p.(Arg273Cys) missense validation 
JB2985T TP53 NM_000546.4 g.chr17:7519260T>C c.395A>G  p.(Lys132Arg) missense validation 
JB3014T  TP53 NM_000546.4 g.chr17:7517840A>G c.823T>C p.(Cys275Arg) missense validation 
JB3953T TP53 NM_000546.4 g.chr17:7518290T>C c.716A>G p.(Asn239Ser) missense validation 
JB938T TP53 NM_000546.4 g.chr17:7518263C>T c.743G>A p.(Arg248Gln) missense validation 
JH108T TP53 NM_000546.4 g.chr17:7519129A>G c.526T>C p.(Cys176Arg) missense validation 
JH666T TP53 NM_000546.4 g.chr17:7518937G>A c.637C>T p.(Arg213*) nonsense validation 
702TS PIK3CA NM_006218.2 g.chr3:180410668G>A c.1252G>A p.(Glu418Lys) missense discovery 
863TCS PIK3CA NM_006218.2 g.chr3:180400172G>A c.353G>A p.(Gly118Asp) missense discovery 
FM403T PIK3CA NM_006218.2 g.chr3:180405018G>A c.1093G>A p.(Glu365Lys) missense discovery 
FM474T PIK3CA NM_006218.2 g.chr3:180404243T>G c.1031T>G p.(Val344Gly) missense discovery 
3FFPE PIK3CA NM_006218.2 g.chr3:180434779A>G c.3140A>G p.(His1047Arg) missense validation 
5FFPE PIK3CA NM_006218.2 g.chr3:180418786A>C c.1634A>C p.(Glu545Ala) missense validation 
5FFPE PIK3CA NM_006218.2 g.chr3:180418810del c.1658del p.(Ser553Ilefs*7) frameshift validation 
5FFPE PIK3CA NM_006218.2 g.chr3:180434779A>G c.3140A>G p.(His1047Arg) missense validation 
7FFPE PIK3CA NM_006218.2 g.chr3:180434766A>G c.3127A>G p.(Met1043Val) missense validation 
10FFPE PIK3CA NM_006218.2 g.chr3:180399618C>T c.311C>T p.(Pro104Leu) missense validation 
10FFPE PIK3CA NM_006218.2 g.chr3:180434658G>C c.3019G>C p.(Gly1007Arg) missense validation 
19FFPE PIK3CA NM_006218.2 g.chr3:180434779A>G c.3140A>G p.(His1047Arg) missense validation 




2910T PIK3CA NM_006218.2 g.chr3:180418785G>A c.1633G>A p.(Glu545Lys) missense validation 
34347T PIK3CA NM_006218.2 g.chr3:180399624G>T c.317G>T p.(Gly106Val) missense validation 
34451T PIK3CA NM_006218.2 g.chr3:180399638A>G c.331A>G p.(Lys111Glu) missense validation 
4435T PIK3CA NM_006218.2 g.chr3:180418770C>G c.1618C>G p.(Leu540Val) missense validation 
62958 PIK3CA NM_006218.2 g.chr3:180418785G>A c.1633G>A p.(Glu545Lys) missense validation 
EM66 PIK3CA NM_006218.2 g.chr3:180399635_180399637del c.328_330del p.(Glu110del) 
in-frame 
indel validation 
JB2411T PIK3CA NM_006218.2 g.chr3:180410674T>C c.1258T>C p.(Cys420Arg) missense validation 
JB2985T PIK3CA NM_006218.2 g.chr3:180434779A>G c.3140A>G p.(His1047Arg) missense validation 
366TS FBXW7 NM_033632.2 g.chr4:153468834C>T c.1394G>A p.(Arg465His) missense discovery 
900T FBXW7 NM_033632.2 g.chr4:153468835G>A c.1393C>T p.(Arg465Cys) missense discovery 
DM851T FBXW7 NM_033632.2 g.chr4:153468834C>A c.1394G>T p.(Arg465Leu) missense discovery 
1FFPE FBXW7 NM_033632.2 g.chr4:153468910C>T c.1318G>A p.(Asp440Asn) missense validation 
1FFPE FBXW7 NM_033632.2 g.chr4:153471333del c.1122+1del p.? splice site  validation 
6FFPE FBXW7 NM_033632.2 g.chr4:153466745C>T c.1507G>A p.(Ala503Thr) missense validation 
7FFPE FBXW7 NM_033632.2 g.chr4:153468834C>T c.1394G>A p.(Arg465His) missense validation 
16FFPE FBXW7 NM_033632.2 g.chr4:153468835G>A c.1393C>T p.(Arg465Cys) missense validation 
19FFPE FBXW7 NM_033632.2 g.chr4:153468835G>A c.1393C>T p.(Arg465Cys) missense validation 
23FFPE FBXW7 NM_033632.2 g.chr4:153468811del c.1417del p.(Arg473Glufs*25) frameshift validation 
31FFPE FBXW7 NM_033632.2 g.chr4:153466739G>A c.1513C>T p.(Arg505Cys) missense validation 
32FFPE FBXW7 NM_033632.2 g.chr4:153468834C>T c.1394G>A p.(Arg465His) missense validation 
2360T FBXW7 NM_033632.2 g.chr4:153466739G>T c.1513C>A p.(Arg505Ser) missense validation 
2748T FBXW7 NM_033632.2 g.chr4:153468835G>A c.1393C>T p.(Arg465Cys) missense validation 
64646 FBXW7 NM_033632.2 g.chr4:153468907G>A c.1321C>T p.(Arg441Trp) missense validation 
JB2985T FBXW7 NM_033632.2 g.chr4:153468835G>A c.1393C>T p.(Arg465Cys) missense validation 
555TS PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense discovery 
702TS PPP2R1A NM_014225.5 g.chr19:57408135C>A c.767C>A p.(Ser256Tyr) missense discovery 
1FFPE PPP2R1A NM_014225.5 g.chr19:57408137T>G c.769T>G  p.(Trp257Gly) missense validation 
3FFPE PPP2R1A NM_014225.5 g.chr19:57408135C>T c.767C>T p.(Ser256Phe) missense validation 
15FFPE PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
26FFPE PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
2910T PPP2R1A NM_014225.5 g.chr19:57407794C>T c.547C>T p.(Arg183Trp) missense validation 
30020T PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
34451T PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
4435T PPP2R1A NM_014225.5 g.chr19:57407794C>T c.547C>T p.(Arg183Trp) missense validation 
62958 PPP2R1A NM_014225.5 g.chr19:57408139G>C c.771G>C p.(Trp257Cys) missense validation 
JB2411T PPP2R1A NM_014225.5 g.chr19:57407794C>T c.547C>T p.(Arg183Trp) missense validation 
JB3953T PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
JB938T PPP2R1A NM_014225.5 g.chr19:57407783C>G c.536C>G p.(Pro179Arg) missense validation 
*Coordinates refer to human reference genome hg18 release (NCBI 





Samples evaluated for TERT promoter mutations 












TOK1 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK2 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK3 ovary clear cell carcinoma c.-124C>T positive n/a Japan FFPE 
TOK4 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK5 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK6 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK7 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK8 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK9 ovary clear cell carcinoma c.-124C>T positive n/a Japan FFPE 
TOK10 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK11 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK12 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK13 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK14 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK15 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK16 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK17 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK18 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK19 ovary clear cell carcinoma c.-124C>T negative n/a Japan FFPE 
TOK21 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK22 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK23 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK24 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK25 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK26 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK27 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK28 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK29 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK30 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK31 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK32 ovary clear cell carcinoma c.-124C>T positive n/a Japan FFPE 
TOK33 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK34 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK35 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK36 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK37 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK38 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK39 ovary clear cell carcinoma none positive n/a Japan FFPE 




TOK41 ovary clear cell carcinoma c.-124C>T positive n/a Japan FFPE 
TOK42 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK43 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK44 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK45 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK46 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK47 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK48 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK49 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK52 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK53 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK54 ovary clear cell carcinoma c.-124C>T positive n/a Japan FFPE 
TOK55 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK56 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK57 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK58 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK59 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK60 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK61 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK62 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK63 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK64 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK65 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK66 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK67 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK68 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK69 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
TOK70 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK71 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK72 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK73 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK74 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK75 ovary clear cell carcinoma c.-146C>T positive n/a Japan FFPE 
TOK76 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK77 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
TOK78 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK79 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK80 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK82 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK83 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK85 ovary clear cell carcinoma none negative n/a Japan FFPE 
TOK86 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK87 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK88 ovary clear cell carcinoma none positive n/a Japan FFPE 
TOK89 ovary clear cell carcinoma none negative n/a Japan FFPE 
TPE1 ovary clear cell carcinoma none negative none Taiwan FFPE 




TPE3 ovary clear cell carcinoma c.-124C>T negative none Taiwan FFPE 
TPE5 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE8 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE9 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE10 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE12 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE13 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE14 ovary clear cell carcinoma none positive p.1047H>R (c.3140A>G) Taiwan FFPE 
TPE17 ovary clear cell carcinoma none negative p.545E>A (c.1634A>C) Taiwan FFPE 
TPE18 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE19 ovary clear cell carcinoma c.-124C>T positive none Taiwan FFPE 
TPE20 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE21 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE22 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE23 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE24 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE25 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE26 ovary clear cell carcinoma none negative p.1021Y>C (c.3062A>G) Taiwan FFPE 
TPE27 ovary clear cell carcinoma c.-124C>T positive none Taiwan FFPE 
TPE28 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE29 ovary clear cell carcinoma none positive p.1049G>R (c.3145G>C) Taiwan FFPE 
TPE30 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE31 ovary clear cell carcinoma c.-124C>T positive none Taiwan FFPE 
TPE32 ovary clear cell carcinoma c.-124C>T positive none Taiwan FFPE 
TPE33 ovary clear cell carcinoma none negative p.1047H>R (c.3140A>G) Taiwan FFPE 
TPE35 ovary clear cell carcinoma c.-124C>T negative none Taiwan FFPE 
TPE36 ovary clear cell carcinoma none positive none Taiwan FFPE 






TPE38 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE39 ovary clear cell carcinoma none positive none Taiwan FFPE 
TPE40 ovary clear cell carcinoma none negative none Taiwan FFPE 
TPE41 ovary clear cell carcinoma none negative p.542E>K (c.1624G>A) Taiwan FFPE 
TPE43 ovary clear cell carcinoma none negative p.1043M>I (c.3129G>A) Taiwan FFPE 
TPE44 ovary clear cell carcinoma none negative p.111K>E (c.331A>G) Taiwan FFPE 
TOR1 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR2 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR3 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR4 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR5 ovary clear cell carcinoma c.-124C>T n/a n/a Canada FFPE 
TOR6 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR7 ovary clear cell carcinoma none negative n/a Canada FFPE 




TOR9 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR10 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR11 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR12 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR13 ovary clear cell carcinoma c.-124C>T positive n/a Canada FFPE 
TOR14 ovary clear cell carcinoma none n/a n/a Canada FFPE 
TOR15 ovary clear cell carcinoma none n/a n/a Canada FFPE 
TOR17 ovary clear cell carcinoma c.-124C>T positive n/a Canada FFPE 
TOR18 ovary clear cell carcinoma c.-146C>T positive n/a Canada FFPE 
TOR19 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR20 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR21 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR22 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR23 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR24 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR25 ovary clear cell carcinoma c.-146C>T positive n/a Canada FFPE 
TOR26 ovary clear cell carcinoma none n/a n/a Canada FFPE 
TOR27 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR28 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR29 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR30 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR31 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR32 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR33 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR34 ovary clear cell carcinoma c.-124C>T positive n/a Canada FFPE 
TOR35 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR36 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR37 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR38 ovary clear cell carcinoma c.-124C>T positive n/a Canada FFPE 
TOR40 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR41 ovary clear cell carcinoma none positive n/a Canada FFPE 
TOR42 ovary clear cell carcinoma none negative n/a Canada FFPE 
TOR43 ovary clear cell carcinoma c.-124C>T positive n/a Canada FFPE 
TOR44 ovary clear cell carcinoma none positive n/a Canada FFPE 
HAM1 ovary clear cell carcinoma none n/a n/a Japan FFPE 
HAM2 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM3 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 
HAM4 ovary clear cell carcinoma c.-124C>T negative none Japan FFPE 
HAM5 ovary clear cell carcinoma none n/a n/a Japan FFPE 
HAM6 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM7 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM8 ovary clear cell carcinoma none negative none Japan FFPE 
HAM9 ovary clear cell carcinoma none positive p.1047H>R (c.3140A>G) Japan FFPE 
HAM10 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 




HAM12 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 
HAM13 ovary clear cell carcinoma none negative p.1047H>R (c.3140A>G) Japan FFPE 
HAM14 ovary clear cell carcinoma c.-124C>T positive p.546Q>R (c.1637A>G) Japan FFPE 
HAM15 ovary clear cell carcinoma none negative p.546Q>K (c.1636C>A) Japan FFPE 
HAM16 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM17 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM18 ovary clear cell carcinoma none negative none Japan FFPE 
HAM19 ovary clear cell carcinoma none negative p.1047H>L (c.3140A>T) Japan FFPE 
HAM20 ovary clear cell carcinoma none negative none Japan FFPE 
HAM21 ovary clear cell carcinoma none positive none Japan FFPE 
HAM22 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 
HAM23 ovary clear cell carcinoma none negative none Japan FFPE 
HAM24 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM25 ovary clear cell carcinoma none negative none Japan FFPE 
HAM26 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 
HAM27 ovary clear cell carcinoma none negative none Japan FFPE 
HAM28 ovary clear cell carcinoma none positive none Japan FFPE 
HAM29 ovary clear cell carcinoma none negative p.545E>K (c.1633G>A) Japan FFPE 
HAM30 ovary clear cell carcinoma none positive p.546Q>R (c.1637A>G) Japan FFPE 
HAM31 ovary clear cell carcinoma none negative none Japan FFPE 
HAM32 ovary clear cell carcinoma none negative p.1047H>R (c.3140A>G) Japan FFPE 
HAM33 ovary clear cell carcinoma none negative none Japan FFPE 
HAM34 ovary clear cell carcinoma c.-124C>T positive none Japan FFPE 
HAM35 ovary clear cell carcinoma none negative p.1049G>R (c.3145G>C) Japan FFPE 
JOC1 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC2 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC3 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC4 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC5 ovary clear cell carcinoma c.-124C>T n/a n/a USA frozen 
JOC6 ovary clear cell carcinoma c.-124C>T n/a n/a USA frozen 
JOC7 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC8 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC9 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC10 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC11 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC12 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC13 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC14 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC15 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC16 ovary clear cell carcinoma c.-124C>T n/a n/a USA frozen 
JOC17 ovary clear cell carcinoma none n/a n/a USA frozen 




JOC19 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC20 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC21 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC22 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC23 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC24 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC25 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC26 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC27 ovary clear cell carcinoma c.-124C>T n/a n/a USA frozen 
JOC28 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC29 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC30 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC31 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC32 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC33 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC34 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC35 ovary clear cell carcinoma none n/a n/a USA frozen 
JOC36 ovary clear cell carcinoma none n/a n/a USA frozen 
ES-2 ovary clear cell carcinoma c.[-138C>T ;-139C>T] n/a none n/a cell line 
JHOC5 ovary clear cell carcinoma c.-124C>T n/a none n/a cell line 
KK ovary clear cell carcinoma none n/a p.545E>A (c.1634A>C) n/a cell line 
KOC-7C ovary clear cell carcinoma none n/a n/a n/a cell line 
OV207 ovary clear cell carcinoma c.-124C>T n/a none n/a cell line 
OVCA429 ovary clear cell carcinoma none n/a p.545E>K (c.1633G>A) n/a cell line 
OVISE ovary clear cell carcinoma none n/a none n/a cell line 
OVMANA ovary clear cell carcinoma none n/a p.545E>V (1634A>T) n/a cell line 
OVTOKO ovary clear cell carcinoma none n/a none n/a cell line 
TOV21G ovary clear cell carcinoma none n/a p.1047H>Y (c.3139C>T) n/a cell line 
OEM1 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM2 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM3 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM4 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM5 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM6 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM7 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM8 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM9 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM10 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM11 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM12 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM13 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM14 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM15 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM16 ovary endometrioid carcinoma none n/a n/a USA frozen 




OEM18 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM19 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM20 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM21 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM22 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM23 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM24 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM25 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM26 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM27 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM28 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM29 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM30 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM31 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM32 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM33 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM34 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM35 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM36 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM37 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM38 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM39 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM40 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM41 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM42 ovary endometrioid carcinoma none n/a n/a USA frozen 
OEM43 ovary endometrioid carcinoma none n/a n/a USA frozen 
JHS1 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS2 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS3 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS4 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS5 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS6 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS7 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS8 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS9 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS10 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS11 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS12 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS13 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS14 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS15 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS16 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS17 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS18 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS19 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS20 ovary high grade serous carcinoma none n/a n/a USA frozen 




JHS22 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS23 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS24 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS25 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS26 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS27 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS28 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS29 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS30 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS31 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS32 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS33 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS34 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS35 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS36 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS37 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS38 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS39 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS40 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS41 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS42 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS43 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS44 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS45 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS46 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS47 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS48 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS49 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS50 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS51 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS52 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS53 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS54 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS55 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS56 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS57 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS58 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS59 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS60 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS61 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS62 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS63 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS64 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS65 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS66 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS67 ovary high grade serous carcinoma none n/a n/a USA frozen 




JHS69 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS70 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS71 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS72 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS73 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS74 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS75 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS76 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS77 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS78 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS79 ovary high grade serous carcinoma none n/a n/a USA frozen 
JHS80 ovary high grade serous carcinoma none n/a n/a USA frozen 
LGS1 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS2 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS3 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS4 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS5 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS6 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS7 ovary low grade serous carcinoma c.-124C>T n/a n/a USA frozen 
LGS8 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS9 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS10 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS11 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS12 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS13 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS14 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS15 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS16 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS17 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS18 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS19 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS20 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS21 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS22 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS23 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS24 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS25 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS26 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS27 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS28 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS29 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS30 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS31 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS32 ovary low grade serous carcinoma none n/a n/a USA frozen 
LGS33 ovary low grade serous carcinoma none n/a n/a USA frozen 
UEM1 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 




UEM3 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM4 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM5 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM6 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM7 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM8 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM9 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM10 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM11 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM12 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM13 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM14 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM15 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM16 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM17 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM18 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM19 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM20 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM21 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM22 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM23 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
UEM24 uterine corpus endometrioid carcinoma none n/a n/a USA frozen 
USC1 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC2 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC3 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC4 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC5 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC6 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC7 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC8 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC9 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC10 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC11 uterine corpus serous carcinoma none n/a n/a USA frozen 
USC12 uterine corpus serous carcinoma none n/a n/a USA frozen 
LMS1 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS2 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS3 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS4 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS5 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS6 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS7 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS8 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS9 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS10 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS11 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS12 uterine corpus leiomyosarcoma none n/a n/a USA frozen 




LMS14 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS15 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS16 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS17 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS18 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS19 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS20 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS21 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
LMS22 uterine corpus leiomyosarcoma none n/a n/a USA frozen 
SCC1 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC2 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC3 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC4 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC5 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC6 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC7 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC8 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC9 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC10 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC11 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC12 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC13 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC14 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC15 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC16 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC17 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC18 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC19 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC20 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC21 uterine cervix squamous cell carcinoma c.-124C>T n/a n/a USA FFPE 
SCC22 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC23 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC24 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC25 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC26 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC27 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC28 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC29 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC30 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC31 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC32 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC33 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC34 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC35 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC36 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC37 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 




SCC39 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC40 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC41 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC42 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC43 uterine cervix squamous cell carcinoma c.-124C>T n/a n/a USA FFPE 
SCC44 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC45 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC46 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC47 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC48 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC49 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC50 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC51 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC52 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
SCC53 uterine cervix squamous cell carcinoma none n/a n/a USA FFPE 
KEN1 uterine cervix endocervical adenocarcinoma none            n/a n/a Korea FFPE 
KEN2 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN3 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN4 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN5 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN6 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN7 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN8 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN9 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN10 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN11 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN12 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN13 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN14 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN15 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN16 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN17 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN18 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN19 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN20 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN21 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN22 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN23 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
KEN24 uterine cervix endocervical adenocarcinoma none n/a n/a Korea FFPE 
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